Therapeutic tb vaccine

ABSTRACT

Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing  tuberculosis.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 10/617,038, filed Jul. 11, 2003, which which claims the benefit of the priority of U.S. Provisional Patent Application No. 60/401,725, filed Aug. 7, 2002, now expired, which applications are incorporated herein by reference.

BACKGROUND OF THE INVENTION

The present invention discloses a therapeutic vaccine against latent or active tuberculosis infection caused by the tuberculosis complex microorganisms (Mycobacterium tuberculosis, M. bovis, M. africanum). The invention furthermore discloses a multi-phase vaccine that can be administered either prophylactically or therapeutically as well as a diagnostic reagent for the detection of latent stages of tuberculosis.

Human tuberculosis caused by Mycobacterium tuberculosis (M. tuberculosis) is a severe global health problem, responsible for approx. 3 million deaths annually, according to the WHO. The worldwide incidence of new tuberculosis (TB) cases had been falling during the 1960s and 1970s but during recent decades this trend has markedly changed in part due to the advent of AIDS and the appearance of multidrug resistant strains of M. tuberculosis.

Organisms of the tuberculosis complex can cause a variety of diseases, but the commonest route of invasion is by inhalation of bacteria. This initiates an infection in the lung, which can ultimately spread to other parts of the body. Normally, this infection is restricted in growth by the immune system, so that the majority of infected individuals show few signs apart from cough and fever, which eventually abates. Approximately 30% of individuals are unable to contain the infection and they will develop primary disease, which in many cases will eventually prove fatal. However, it is believed that even those individuals who apparently control the infection remain infected, probably for the rest of their life. Certainly, individuals who have been healthy for years or even decades can suddenly develop tuberculosis, which has proven to be caused by the same organism they were infected with many years previously. M. tuberculosis and other organisms of the TB complex are unique in that the mycobacteria can evade the immune response and survive for long periods in a refractory non-replicating or slowly-replicating stage. This is referred to as latent TB and is at present a very significant global health problem that is estimated to affect approximately ⅓ of the world's population (Anon., 2001).

The course of a M. tuberculosis infection runs essentially through 3 phases, as illustrated in FIG. 1. During the acute phase, the bacteria proliferate in the organs, until the immune response increases to the point at which it can control the infection, whereupon the bacterial load peaks and starts declining. After this, a latent phase is established where the bacterial load is kept stable at a low level. In this phase M. tuberculosis goes from active multiplication to dormancy, essentially becoming non-replicating and remaining inside the granuloma. In some cases, the infection goes to the reactivation phase, where the dormant bacteria start replicating again. The full nature of the immune response that controls latent infection and the factors that lead to reactivation are largely unknown. However, there is some evidence for a shift in the dominant cell types responsible. While CD4 T cells are essential and sufficient for control of infection during the acute phase, studies suggest that CD8 T cell responses are more important in the latent phase. It is also likely that changes in the antigen-specificity of the response occur, as the bacterium modulates gene expression during its transition from active replication to dormancy.

The only vaccine presently available for clinical use is BCG, a vaccine whose efficacy remains a matter of controversy. Although BCG consistently performs well in animal models of primary infection, it has clearly failed to control the TB epidemic. Consistent with that, BCG vaccination appears to provide protection against pediatric TB (which is due to primary infection), while offering little or no protection against adult disease (which is often reactivation of latent infection acquired in childhood). It has also been shown that vaccination of individuals who are currently sensitized to mycobacteria or latently infected is ineffective. Thus, current vaccination strategies, while effective against primary disease, fail to activate immune responses that efficiently control surviving dormant bacteria.

At this point no vaccine has been developed that confers protection against reactivation whether given as a prophylactic vaccine prior to infection or as a therapeutic vaccine given to already latently infected individuals.

This makes the development of a new and improved vaccine against TB an urgent matter, which has been given a very high priority by the WHO. Many attempts to define protective mycobacterial substances have been made, and different investigators have reported increased resistance after experimental vaccination. However, these efforts have almost exclusively focused on the development of prophylactic vaccines for the prevention of disease (Doherty, 2002), and such vaccines have not been demonstrated to work if given in an immunotherapeutic fashion (J. Turner et al., Infect and Immunity, 2000, pp. 1706-1709).

It has been suggested that the transition of M. tuberculosis from primary infection to latency is accompanied by changes in gene expression (see, for example, Honer zu Bentrup, 2001, which is incorporated herein by reference). In vitro hypoxic culture conditions, which mimic the conditions of low oxygen tension and restricted nutrients found in the granuloma (the location of the latent infection), have been used to analyze changes in gene expression and a number of antigens have been found that are induced or markedly upregulated under these conditions e.g. the 16 kDa antigen α-crystalline (Boon, 2001, Monahan, 2001, Florczyk 2001, Sherman 2001, Manganelli, 2001, all of which are incorporated herein by reference) and Rv0569 as described in Rosenkrands, 2002, and which is described in WO0179274.

As noted in the references cited above, it is already known that some genes are upregulated under conditions that mimic latency. However, these are a limited subset of the total gene expression during latent infection. Moreover, as one skilled in the art will readily appreciate, expression of a gene is not sufficient to make it a good vaccine candidate. The only way to determine if a protein is recognized by the immune system during latent infection with M. tuberculosis is to produce the given protein and test it in an appropriate assay as described herein. Of the more than 200 hundred antigens known to be expressed during primary infection, and tested as vaccines, less than a half dozen have demonstrated significant potential. So far only one antigen has been shown to have any potential as a therapeutic vaccine (Lowrie, 1999). However this vaccine only worked if given as a DNA vaccine, an experimental technique so far not approved for use in humans. Moreover, the technique has proved controversial, with other groups claiming that vaccination using this protocol induces either non-specific protection or even worsens disease (J. Turner et al., Infect and Immunity, 2000, pp. 1706-1709).

What are needed are therapeutic vaccines that treat latent TB infection.

SUMMARY OF THE INVENTION

The present invention provides therapeutic vaccines based on molecules that are induced or upregulated under the conditions of low oxygen transmission and restricted nutrients found in the granuloma (i.e., the location of latent TB infection). These vaccines are therapeutic and contrast with prior art vaccines which are designed to elicit protective immune responses prior to infection (prophylactic vaccination) that are only effective against primary infection. The immune responses elicited are powerless against the latent stage of the disease, because the bacteria have changed the antigens that they produce so that in essence they have altered their appearance and the immune system can no longer recognize them. However, latency is a dynamic process, maintained by the immune response, as indicated by the dramatic increase in the risk of reactivation of TB after HIV infection or other events that compromise immunity. Therefore, an effective vaccination strategy to protect infected individuals (therapeutic vaccination) is possible, but only if it is directed against those antigens expressed in the latent stage.

Further, the present invention provides a multiphase vaccine that combines components with prophylactic and therapeutic activity. In contrast, existing TB vaccines do not result in sterilizing immunity but rather control the infection at a subclinical level (thereby resulting in the subsequent establishment of latent infection. After conventional prophylactic vaccination, the evasion of the primary immune response and the subsequent development of latent disease are probably at least in part due to the change in the antigenic profile of the invading bacteria. Thus, vaccinating with antigens associated with latent TB prevents or reduces the establishment of latent infection and therefore, a vaccine incorporating antigens expressed by the bacteria both in the first logarithmic growth phase and during latent disease improve long-term immunity when used as a prophylactic vaccine. A multiphase vaccine of the invention will also be efficient as a therapeutic vaccine thereby addressing the problem that the majority of the population in the third world who would receive a future TB vaccine could be already latently infected.

For a number of years, a major effort has been put into the identification of protective antigens for the development of novel prophylactic vaccines against TB and today a few antigens with demonstrated protective activity in prophylactic vaccines have been identified (e.g. ESAT-6, the 38 kDa antigen, Ag85A and Ag85B). Such molecules are useful components, which in combination with latency associated antigens such as α-crystalline, form a multiphase vaccine of the invention. Advantageously and in contrast to antigens in the art, the antigens described in the invention are incorporated in vaccines through the use of well-recognized vaccination technology, as demonstrated in provided examples.

Finally, the immunodominant antigens identified in this invention may be used as diagnostic reagents. Our group has abundantly demonstrated that antigens expressed by mycobacteria during the early stages of the infection, such as ESAT-6 (Early Secretory Antigen Target-6) are recognized in individuals who are in the process of developing primary TB, even though they are healthy at the time of diagnosis (Doherty 2002). However, the large numbers of contacts who are exposed, and almost certainly infected, remain negative to this antigen (Doherty 2002). Since those individuals latently infected remain healthy by making an immune response against the latent bacteria, they must be making an immune response to those antigens expressed by the latent bacteria. Thus, the antigens of the invention may also be used to diagnose latent infection and differentiate it from primary acute TB.

Other aspects and advantages of the invention will be readily apparent to one of skill in the art.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B illustrate the results of testing in TB vaccination models. A schematic time schedule of the models for FIG. 1A, prophylactic vaccination and FIG. 1B, therapeutic vaccination. Each square on the time axis represents one week. Three prophylactic vaccinations two weeks apart are given 6 weeks prior to an aerosol infection. The protective effect of the vaccines is measured 6 weeks after infection, in the acute phase of the infection. For analysis of therapeutic vaccinations a reactivation model is established, where aerosol infected mice are treated with anti-M tuberculosis drugs for 8 weeks from the peak of infection (6 weeks after infection). This induces a latent infection phase with a low bacterial load. Four to five weeks into the latency phase three therapeutic vaccinations are given two weeks apart and the protective effect of the vaccines is measured as bacterial load in the reactivation phase, seven weeks after the last immunization.

FIGS. 2A and 2B illustrate prophylactic and therapeutic vaccine induced protection. C57Bl/6j mice were immunized 3 times with a 2-week interval with recombinant ESAT6, BCG or recombinant Rv2031c. In FIG. 2A, the immunization was given as a prophylactic vaccine 6 weeks before the mice were given a M. tuberculosis infection (approx. 250 bacilli) through the aerosol route with. Bacterial numbers in the lung was enumerated 6 weeks post infection. In FIG. 2B, the immunization was given as a therapeutic vaccine after a latent infection had been established. Bacterial numbers in the lung was enumerated 8 weeks after the last immunization. The data represents the mean of 5 individual mice.

FIG. 3 illustrates Rv2031c specific IFN-γ responses. Latent infected C57Bl/6j mice were either not immunized or immunized with 3 μg recombinant Rv2031 3 times with a two-week interval. One and two weeks post immunization mice were bleed and PBMCs isolated. The frequency of IFN-γ producing cells specific for either ESAT6 or Rv2031c was determined for both the rRv2031c immunized and the unimmunized group. In an ELIspot plate precoated with anti-IFN-γ antibodies graded numbers of PBMCs were incubated with either 2 μg/ml rRv2031c or 2 μg/ml rESAT6. After 32 h the plate was washed and incubated with biotinylated anti-INF-γ antibodies followed by a streptavidin-alkalinephosphatase incubation. The INFγ spots, representing individual IFN-γ producing cells were visualized using BCIP/NBT substrate. The results are shown as number Rv2031c specific IFN-γ producing cell (black bars) and number of ESAT6 specific IFN-γ producing cell (hatch bars) per 10⁶ PBMCs.

FIGS. 4A and 4B illustrate the results of epitope screening of Rv2031c. PBMCs from rRv2031c immunized latently infected C57Bl/6j mice were analyzed for recognition of 20′ mer overlapping peptides scanning through Rv2031c. In FIG. 4A, the peptides were analyzed in pools of 3-4 peptides. PBMCs (2×10⁵) were incubated for 72 h with the peptide pools at 5 μg/ml per peptide. Supernatant was harvested and secreted IFN-γ was quantitated by ELISA. In FIG. 4B, individual peptides of positive pools were reanalyzed. PBMCs (2×10⁵) were incubated for 72 h with 1 μg/ml of each peptide. Secreted IFN-γ in the supernatant was quantitated.

FIGS. 5A and 5B illustrate protection against reactivation conferred by therapeutic vaccine given during latent infection. Latent infected C57Bl/6j mice were immunized 3 times with or without rRv2031c. Bacterial numbers in lung (FIG. 5A) and spleen (FIG. 5B) was enumerated 8 weeks after the last immunization. The data represents the mean of 8 individual mice.

FIGS. 6A and 6B illustrate Rv0569 specific IFN-γ responses. Latent infected C57Bl/6j mice were vaccinated with 3 μg of either recombinant Rv0569 or recombinant ESAT6 in a DDA/MPL adjuvant. The vaccines were given as 3 s.c. injections with a two-week interval and the induced immune response were evaluated 7 weeks after the last vaccination. Isolated splenocytes (2×10⁵) were incubated for 72 h with antigen at 1 μg/ml. Supernatant was harvested and secreted IFN-γ was quantitated by ELISA using paired anti-murine IFN-γ antibodies (PharMingen) and recombinant IFN-γ (PharMingen) as standard. In FIG. 6A, Rv0569 specific response is measured in Rv0569-vaccinated and un-vaccinated latently infected mice; in FIG. 6B, the ESAT6 specific response is measured in ESAT6-vaccinated and un-vaccinated latently infected mice

FIGS. 7A and 7B illustrate therapeutic vaccine induced protection against reactivation. Latently infected C57Bl/6j mice were vaccinated once with BCG or 3 times with a 2-week interval with either recombinant Rv0569 or recombinant ESAT6. Seven weeks after the last vaccination the bacterial numbers was enumerated in FIG. 7A, the lung and in FIG. 7B, the spleen of vaccinated and un-vaccinated mice. The data represents the mean of Log CFU per organ of 6-8 individual mice.

DETAILED DESCRIPTION OF THE INVENTION

The invention is related to preventing, treating and detecting infections caused by species of the tuberculosis complex (Mycobacterium tuberculosis, M. bovis, M. africanum) by the use of a polypeptide comprising a M. tuberculosis antigen or an immunogenic portion or other variant thereof, or by the use of a DNA sequence encoding a M. tuberculosis antigen or an immunogenic portion or other variant thereof. The invention discloses a new therapeutic vaccine against tuberculosis comprising antigens induced during the latent stage of TB-infection. It also discloses a multiphase vaccine incorporating a combination of prophylactic and therapeutic antigens as well as diagnostic reagents for the detection of the latent stage of M. tuberculosis infection.

The present invention discloses the use of one or more polypeptides, nucleic acids encoding these polypeptides or fragments hereof, which polypeptides are expressed during the latent stage of the mycobacteria infection, which stage is characterized by low-oxygen tension in the microenvironment of the mycobacteria, for a therapeutic vaccine against tuberculosis.

The polypeptides comprises one or more amino acid sequences selected from

-   -   (a) The sequences presented in Table 1.     -   (b) an immunogenic portion, e.g. a T-cell epitope, of any one of         the sequences in (a); and/or     -   (c) an amino acid sequence analogue having at least 70% sequence         identity to any one of the sequences in (a) or (b) and at the         same time being immunogenic.

TABLE 1 Amino acid sequences of selected low oxygen induced antigens SEQ ID Rv no. NO: Sequence Rv0569 91 MKAKVGDWLVIKGATIDQPDHRGLIIEVRSSDGSPPYVVRWLETDHVATV IPGPDAVVVTAEEQNAADERAQHRFGAVQSAILHARGT Rv0079 1 VEPKRSRLVVCAPEPSHAREFPDVAVFSGGRANASQAERLARAVGRVLAD RGVTGGARVRLTMANCADGPTLVQINLQVGDTPLRAQAATAGIDDLRPAL IRLDRQIVRASAQWCPRPWPDRPRRRLTTPAEALVTRRKPVVLRRATPLQ AIAAMDAMDYDVHLFTDAETGEDAVVYRAGPSGLRLARQHHVFPPGWSRC RAPAGPPVPLIVNSRPTPVLTEAAAVDRAREHGLPFLFFTDQATGRGQLL YSRYDGNLGLITPTGDGVADGLA Rv0080 2 MSPGSRRASPQSAREVVELDRDEAMRLLASVDHGRVVFTRAALPAIRPVN HLVVDGRVIGRTRLTAKVSVAVRSSADAGVVVAYEADDLDPRRRTGWSVV VTGLATEVSDPEQVARYQRLLHPWVNMAMDTVVAIEPEIVTGIRIVADSR TP Rv0081 3 VESEPLYKLKAEFFKTLAHPARIRILELLVERDRSVGELLSSDVGLESSN LSQQLGVLRRAGVVAARRDGNAMIYSIAAPDIAELLAVARKVLARVLSDR VAVLEDLRAGGSAT Rv0363c 4 MPIATPEVYAEMLGQAKQNSYAFPAINCTSSETVNAAIKGFADAGSDGII QFSTGGAEFGSGLGVKDMVTGAVALAEFTHVIAAKYPVNVALHTDHCPKD KLDSYVRPLLAISAQRVSKGGNPLFQSHMWDGSAVPIDENLAIAQELLKA AAAAKIILEIEIGVVGGEEDGVANEINEKLYTSPEDFEKTIEALGAGEHG KYLLAATFGNVHGVYKPGNVKLRPDILAQGQQVAAAKLGLPADAKPFDFV FHGGSGSLKSEIEEALRYGVVKMNVDTDTQYAFTRPIAGHMFTNYDGVLK VDGEVGVKKVYDPRSYLKKAEASMSQRVVQACNDLHCAGKSLTH Rv0572c 5 MGEHAIKRHMRQRKPTKHPLAQKRGARILVFTDDPRRSVLIVPGCHLDSM RREKNAYYFQDGNALVGMVVSGGTVEYDADDRTYVVQLTDGRHTTESSFE HSSPSRSPQSDDL Rv0574c 6 VAGNPDVVTVLLGGDVMLGRGVDQILPHPGKPQLRERYMRDATGYVRLAE RVNGRIPLPVDWRWPWGEALAVLENTATDVCLINLETTITADGEFADRKP VCYRMHPDNVPALTALRPHVCALANNHILDFGYQGLTDTVAALAGAGIQS VGAGADLLAARRSALVTVGHERRVIVGSVAAESSGVPESWAARRDRPGVW LIRDPAQRDVADDVAAQVLADKRPGDIAIVSMHWGSNWGYATAPGDVAFA HRLIDAGIDMVHGHSSHHPRPIEIYRGKPILYGCGDVVDDYEGIGGHESF RSELRLLYLTVTDPASGNLISLQMLPLRVSRMRLQRASQTDTEWLRNTIE RISRRFGIRVVTRPDNLLEVVPAANLTSKE Rv1264 7 VTDHVREADDANIDDLLGDLGGTARAERAKLVEWLLEQGITPDEIRATNP PLLLATRHLVGDDGTYVSAREISENYGVDLELLQRVQRAVGLARVDDPDA VVHMRADGEAAARAQRFVELGLNPDQVVLVVRVLAEGLSHAAEAMRYTAL EAIMRPGATELDIAKGSQALVSQIVPLLGPMIQDMLFMQLRHMMETEAVN AGERAAGKPLPGARQVTVAFADLVGFTQLGEVVSAEELGHLAGRLAGLAR DLTAPPVWFIKTIGDAVMLVCPDPAPLLDTVLKLVEVVDTDNNFPRLRAG VASGMAVSRAGDWFGSPVNVASRVTGVARPGAVLVADSVREALGDAPEAD GFQWSFAGPRRLRGIRGDVRLFRVRRGATRTGSGGAAQDDDLAGSSP Rv1592c 8 MVEPGNLAGATGAEWIGRPPHEELQRKVRPLLPSDDPFYFPPAGYQHAVP GTVLRSRDVELAFMGLIPQPVTATQLLYRTTNMYGNPEATVTTVIVPAEL APGQTCPLLSYQCAIDAMSSRCFPSYALRRRAKALGSLTQMELLMISAAL AEGWAVSVPDHEGPKGLWGSPYEPGYRVLDGIRAALNSERVGLSPATPIG LWGYSGGGLASAWAAEACGEYAPDLDIVGAVLGSPVGDLGHTFRRLNGTL LAGLPALVVAALQHSYPGLARVIKEHANDEGRQLLEQLTEMTTVDAVIRM AGRDMGDFLDEPLEDILSTPEISHVFGDTKLGSAVPTPPVLIVQAVHDYL IDVSDIDALADSYTAGGANVTYHRDLFSEHVSLHPLSAPMTLRWLTDRFA GKPLTDHRVRTTWPTIFNPMTYAGMARLAVIAAKVITGRKLSRRPL Rv1733c 9 MIATTRDREGATMITFRLRLPCRTILRVFSRNPLVRGTDRLEAVVMLLAV TVSLLTIPFAAAAGTAVQDSRSHVYAHQAQTRHPATATVIDHEGVIDSNT TATSAPPRTKITVPARWVVNGIERSGEVNAKPGTKSGDRVGIWVDSAGQL VDEPAPPARAIADAALAALGLWLSVAAVAGALLALTRAILIRVRNASWQH DIDSLFCTQR Rv1734c 10 MTNVGDQGVDAVFGVIYPPQVALVSFGKPAQRVCAVDGAIHVMTTVLATL PADHGCSDDHRGALFFLSINELTRCAAVTG Rv1736c 11 VTVTPRTGSRIEELLARSGRFFIPGEISADLRTVTRRGGRDGDVFYRDRW SHDKVVRSTHGVNCTGSCSWKIYVKDDIITWETQETDYPSVGPDRPEYEP RGCPRGAAFSWYTYSPTRVRHPYARGVLVEMYREAKARLGDPVAAWADIQ ADPRRRRRYQRARGKGGLVRVSWAEATEMIAAAHVHTISTYGPDRVAGFS PIPAMSMVSHAAGSRFVELIGGVMTSFYDWYADLPVASPQVFGDQTDVPE SGDWWDVVWQCASVLLTYPNSRQLGTAEELLAHIDGPAADLLGRTVSELR RADPLTAATRYVDTFDLRGRATLYLTYWTAGDTRNRGREMLAFAQTYRST DVAPPRGETPDFLPVVLEFAATVDPEAGRRLLSGYRVPIAALCNALTEAA LPYAHTVAAVCRTGDMMGELFWTVVPYVTMTIVAVGSWWRYRYDKFGWTT RSSQLYESRLLRIASPMFHFGILVVIVGHGIGLVIPQSWTQAAGLSEGAY HVQAVVLGSIAGITTLAGVTLLIYRRRTRGPVFMATTVNDKVMYLVLVAA IVAGLGATALGSGVVGEAYNYRETVSVWFRSVWVLQPRGDLMAEAPLYYQ IHVLIGLALFALWPFTRLVHAFSAPIGYLFRPYIIYRSREELVLTRPRRR GW Rv1737c 12 MRGQAANLVLATWISVVNFWAWNLIGPLSTSYARDMSLSSAEASLLVATP ILVGALGRIVTGPLTDRFGGRAMLIAVTLASILPVLAVGVAATMGSYALL VFFGLFLGVAGTIFAVGIPFANNWYQPARRGFSTGVFGMGMVGTALSAFF TPRFVRWFGLFTTHAIVAAALASTAVVAMVVLRDAPYFRPNADPVLPRLK AAARLPVTWEMSFLYAIVFGGFVAFSNYLPTYITTIYGFSTVDAGARTAG FALAAVLARPVGGWLSDRIAPRHVVLASLAGTALLAFAAALQPPPEVWSA ATFITLAVCLGVGTGGVFAWVARRAPAASVGSVTGIVAAAGGLGGYFPPL VMGATYDPVDNDYTVGLLLLVATALVACTYTALHAREPVSEEASR Rv1738c 13 MCGDQSDHVLQHWTVDISIDEHEGLTRAKARLRWREKELVGVGLARLNPA DRNVPEIGDELSVARALSDLGKRMLKVSTHDIEAVTHQPARLLY Rv1739c 14 MIPTMTSAGWAPGVVQFREYQRRWLRGDVLAGLTVAAYLIPQAMAYATVA GLPPAAGLWASIAPLAIYALLGSSRQLSIGPESATALMTAAVLAPMAAGD LRRYAVLAATLGLLVGLICLLAGTARLGFLASLRSRPVLVGYMAGIALVM ISSQLGTITGTSVEGNEFFSEVHSFATSVTRVHWPTFVLAMSVLALLTML TRWAPRAPGPIIAVLAATMLVAVMSLDAKGIAIVGRIPSGLPTPGVPPVS VEDLRALIIPAAGIAIVTFTDGVLTARAFAARRGQEVNANAELRAVGACN IAAGLTHGFPVSSSSSRTALADVVGGRTQLYSLIALGLVVIVMVFASGLL AMFPIAALGALVVYAALRLIDLSEFRRLARFRRSELMLALATTAAVLGLG VFYGVLAAVALSILELLRRVAHPHDSVLGFVPGIAGMHDIDDYPQAKRVP GLVVYRYDAPLCFANAEDFRRRALTVVDQDPGQVEWFVLNAESNVEVDLT ALDALDQLRTELLRRGIVFAMARVKQDLRESLRAASLLDKIGEDHIFMTL PTAVQAFRRR Rv1813c 15 MITNLRRRTAMAAAGLGAALGLGILLVPTVDAHLANGSMSEVMMSE IAGLPIPPIIHYGAIAYAPSGASGKAWHQRTPARAEQVALEKCGDK TCKVVSRFTRCGAVAYNGSKYQGGTGLTRRAAEDDAVNRLEGGRIV NWACN Rv1997c 16 LSASVSATTAHHGLPAHEVVLLLESDPYHGLSDGEAAQRLERFGPNTLAV VTRASLLARILRQFHHPLIYVLLVAGTITAGLKEFVDAAVIFGVVVINAI VGFIQESKAEAALQGLRSMVHTHAKVVREGHEHTMPSEELVPGDLVLLAA GDKVPADLRLVRQTGLSVNESALTGESTPVHKDEVALPEGTPVADRRNIA YSGTLVTAGHGAGIVVATGAETELGEIHRLVGAAEVVATPLTAKLAWFSK FLTIAILGLAALTFGVGLLRRQDAVETFTAAIALAVGAIPEGLPTAVTIT LAIGMARMAKRRAVIRRLPAVETLGSTTVICADKTGTLTENQMTVQSIWT PHGEIRATGTGYAPDVLLCDTDDAPVPVNANAALRWSLLAGACSNDAALV RDGTRWQIVGDPTEGAMLVVAAKAGFNPERLATTLPQVAAIPFSSERQYM ATLHRDGTDHVVLAKGAVERMLDLCGTEMGADGALRPLDRATVLRATEML TSRGLRVLATGMGAGAGTPDDFDENVIPGSLALTGLQAMSDPPRAAAASA VAACHSAGIAVKMITGDHAGTATAIATEVGLLDNTEPAAGSVLTGAELAA LSADQYPEAVDTASVFARVSPEQKLRLVQALQARGHVVAMTGDGVNDAPA LRQANIGVAMGRGGTEVAKDAADMVLTDDDFATIEAAVEEGRGVFDNLTK FITWTLPTNLGEGLVILAAIAVGVALPILPTQILWINMTTAIALGLMLAF EPKEAGIMTRPPRDPDQPLLTGWLVRRTLLVSTLLVASAWWLFAWELDNG AGLHEARTAALNLFVVVEAFYLFSCRSLTRSAWRLGMFANRWIILGVSAQ AIAQFAITYLPAMNMVFDTAPIDIGVWVRIFAVATAITIVVATDTLLPRI RAQPP Rv1998c 17 MSFHDLHHQGVPFVLPNAWDVPSALAYLAEGFTAIGTTSFGVSSSGGHPD GHRATRGANIALAAALAPLQCYVSVDIEDGYSDEPDAIADYVAQLSTAGI NIEDSSAEKLIDPALAAAKIVAIKQRNPEVFVNARVDTYWLRQHADTTSTT IQRALRYVDAGADGVFVPLANDPDELAELTRNIPCPVNTLPVPGLTIADL GELGVARVSTGSVPYSAGLYAAAHAARAVSDGEQLPRSVPYAELQARLVD YENRTSTT RV2003c 18 VVKRSRATRLSPSIWSGWESPQCRSIRARLLLPRGRSRPPNADCCWNQLA VTPDTRMPASSAAGRDAAAYDAWYDSPTGRPILATEVAALRPLIEVFAQP RLEIGVGTGRFADLLGVRFGLDPSRDALMFARRRGVLVANAVGEAVPFVS RHFGAVLMAFTLCFVTDPAAIFRETRRLLADGGGLVIGFLPRGTPWADLY ALRAARGQPGYRDARFYTAAELEQLLADSGFRVIARRCTLHQPPGLARYD IEAAHDGIQAGAGFVAISAVDQAHEPKDDHPLESE RV2005c 19 MSKPRKQHGVVVGVDGSLESDAAACWGATDAAMRNIPLTVVHVVNADVAT WPPMPYPETWGVWQEDEGRQIVANAVKLAKEAVGADRKLSVKSELVFSTP VPTMVEISNEAEMVVLGSSGRGALARGLLGSVSSSLVRRAGCPVAVIHSD DAVIPDPQHAPVLVGIDGSPVSELATAVAFDEASRRGVELIAVHAWSDVE VVELPGLDFSAVQQEAELSLAERLAGWQERYPDVPVSRVVVCDRPARKLV QKSASAQLVVVGSHGRGGLTGMLLGSVSNAVLHAARVPVIVARQS Rv2007c 20 VTYVIGSECVDVMDKSCVQECPVDCIYEGARMLYINPDECVDCGACKPAC RVEAIYWEGDLPDDQHQHLGDNAAFFHQVLPGRVAPLGSPGGAAAVGPIG VDTPLVAAIPVECP Rv2028c 21 MNQSHKPPSIVVGIDGSKPAVQAALWAVDEAASRDIPLRLLYAIEPDDPG YAAHGAAARKLAAAENAVRYAFTAVEAADRPVKVEVEITQERPVTSLIRA SAAAALVCVGAIGVHHFRPERVGSTAAALALSAQCPVAIVRPHRVPIGRD AAWIVVEADGSSDIGVLLGAVMAEARLRDSPVRVVTCRQSGVGDTGDDVR ASLDRWLARWQPRYPDVRVQSAAVHGELLDYLAGLGRSVHMVVLSASDQE HVEQLVGAPGNAVLQEAGCTLLVVGQQYL Rv2029c 22 MTEPAAWDEGKPRIITLTMNPALDITTSVDVVRPTEKMRCGAPRYDPGGG GINVARIVHVLGGCSTALFPAGGSTGSLLMALLGDAGVPFRVIPIAASTR ESFTVNESRTAKQYRFVLPGPSLTVAEQEQCLDELRGAAASAAFVVASGS LPPGVAADYYQRVADICRRSSTPLILDTSGGGLQHISSGVFLLKASVREL RECVGSELLTEPEQLAAAHELIDRGRAEVVVVSLGSQGALLATRHASHRF SSIPMTAVSGVGAGDAMVAAITVGLSRGWSLIKSVRLGNAAGAAMLLTPG TAACNRDDVERFFELAAEPTEVGQDQYVWHPIVNPEASP Rv2030c 23 VLMTAAADVTRRSPRRVFRDRREAGRVLAELLAAYRDQPDVIVLGLARGG LPVAWEVAAALHAPLDAFVVRKLGAPGHDEFAVGALASGGRVVVNDDVVR GLRITPQQLRDIAEREGRELLRRESAYRGERPPTDITGKTVIVVDDGLAT GASMFAAVQALRDAQPAQIVIAVPAAPESTCREFAGLVDDVVCATMPTPF LAVGESFWDFRQVTDEEVRRLLATPTAGPSLRRPAASTAADVLRRVAIDA PGGVPTHEVLAELVGDARIVLIGESSHGTHEFYQARAAMTQWLIEEKGFG AVAAEADWPDAYRVNRYVRGLGEDTNADEALSGFERFPAWMWRNTVVRDF VEWLRTRNQRYESGALRQAGFYGLDLYSLHRSIQEVISYLDKVDPRAAAR ARARYACFDHACADDGQAYGFAAAFGAGPSCEREAVEQLVDVQRNALAYA RQDGLLAEDELFYAQQNAQTVRDAEVYYRAMFSGRVTSWNLRDQHMAQTL GSLLTHLDRHLDAPPARIVVWAHNSHVGDARATEVWADGQLTLGQIVRER YGDESRSIGFSTYTGTVTAASEWGGIAQRKAVRPALHGSVEELFHQTADS FLVSARLSRDAEAPLDVVRLGRAIGVVYLPATERQSHYLHVRPADQFDAM IHIDQTRALEPLEVTSRWIAGENPETYPTGL Rv2031c 24 MATTLPVQRHPRSLFPEFSELFAAFPSFAGLRPTFDTRLMRLEDEMKEGR YEVRAELPGVDPDKDVDIMVRDGQLTIKAERTEQKDFDGRSEFAYGSPVR TVSLPVGADEDDIKATYDKGILTVSVAVSEGKPTEKHIQIRSTN Rv2032 25 MPDTMVTTDVIKSAVQLACRAPSLHNSQPWRWIAEDHTVALFLDKDRVLY ATDHSGREALLGCGAVLDHFRVAMAAAGTTANVERFPNPNDPLHLASIDF SPADFVTEGHRLRADAILLRRTDRLPFAEPPDWDLVESQLRTTVTADTVR IDVIADDMRPELAAASKLTESLRLYDSSYHAELFWWTGAFETSEGIPHSS LVSAAESDRVTFGRDFPVVANTDRRPEFGHDRSKVLVLSTYDNERASLLR CGEMLSAVLLDATMAGLATCTLTHITELHASRDLVAALIGQPATPQALVR VGLAPEMEEPPPATPRRPIDEVFHVRAKDHR Rv2428 26 MPLLTIGDQFPAYQLTALIGGDLSKVDAKQPGDYFTTITSDEHPGKWRVV FFWPKDFTFVCPTEIAAFSKLNDEFEDRDAQILGVSIDSEFAHFQWRAQH NDLKTLPFPMLSDIKRELSQAAGVLNADGVADRVTFIVDPNNEIQFVSAT AGSVGRNVDEVLRVLDALQSDELCACNWRKGDPTLDAGELLKASA Rv2624c 27 MSGRGEPTMKTIIVGIDGSHAAITAALWGVDEAISRAVPLRLVSVIKPTH PSPDDYDRDLAHAERSLREAQSAVEAAGKLVKIETDIPRGPAGPVLVEAS RDAEMICVGSVGIGRYASSILGSTATELAEKAHCPVAVMRSKVDQPASDI NWIVVRMTDAPDNEAVLEYAAREAKLRQAPILALGGRPEELREIPDGEFE RRVQDWHHRHPDVRVYPITTHTGIARFLADHDERVQLAVIGGGEAGQLAR LVGPSGHPVFRHAECSVLVVRR Rv2625c 28 MRDAIPLGRIAGFVVNVHWSVLVILWLFTWSLATMLPGTVGGYPAVVYWL LGAGGAVMLLASLLAHELAHAVVARRAGVSVESVTLWLFGGVTALGGEAK TPKAAFRIAFAGPATSLALSATFGALAITLAGVRTPAIVISVAWWLATVN LLLGLFNLLPGAPLDGGRLVRAYLWRRHGDSVRAGIGAARAGRVVALVLI ALGLAEFVAGGLVGGVWLAFIGWFIFAAAREEETRISTQQLFAGVRVADA MTAQPHTAPGWINVEDFIQRYVLGERHSAYPVADRDGSITGLVALRQLRD VAPSRRSTTSVGDIALPLHSVPTARPQEPLTALLERMAPLGPRSRALVTE GSAVVGIVTPSDVARLIDVYRLAQPEPTFTTSPQDADRFSDAG Rv2727c 29 MASSASDGTHERSAFRLSPPVLSGAMGPFMHTGLYVAQSWRDYLGQQPDK LPIARPTIALAAQAFRDEIVLLGLKARRPVSNHRVFERISQEVAAGLEFY GNRRWLEKPSGFFAQPPPLTEVAVRKVKDRRRSFYRIFFDSGFTPHPGEP GSQRWLSYTANNREYALLLRHPEPRPWLVCVHGTEMGRAPLDLAVFRAWK LHDELGLNIVMPVLPMHGPRGQGLPKGAVFPGEDVLDDVHGTAQAVWDIR RLLSWIRSQEEESLIGLNGLSLGGYIASLVASLEEGLACAILGVPVADLI ELLGRHCGLRHKDPRRHTVKMAEPIGRMISPLSLTPLVPMPGRFIYAGIA DRLVHPREQVTRLWEHWGKPEIVWYPGGHTGFFQSRPVRRFVQAALEQSG LLDAPRTQRDRSA Rv2628 30 MSTQRPRHSGIRAVGPYAWAGRCGRIGRWGVHQEAMMNLAIWHPRKVQSA TIYQVTDRSHDGRTARVPGDEITSTVSGWLSELGTQSPLADELARAVRIG DWPAAYAIGEHLSVEIAVAV Rv2629 31 MRSERLRWLVAAEGPFASVYFDDSHDTLDAVERREATWRDVRKHLESRDA KQELIDSLEEAVRDSRPAVGQRGRALIATGEQVLVNEHLIGPPPATVIRL SDYPYVVPLIDLEMRRPTYVFAAVDHTGADVKLYQGATISSTKIDGVGYP VHKPVTAGWNGYGDFQHTTEEAIRMNCRAVADHLTRLVDAADPEVVFVSG EVRSRTDLLSTLPQRVAVRVSQLHAGPRKSALDEEEIWDLTSAEFTRRRY AEITNVAQQFEAEIGRGSGLAAQGLAEVCAALRDGDVDTLIVGELGEATV VTGKARTTVARDADMLSELGEPVDRVARADEALPFAAIAVGAALVRDDNR IAPLDGVGALLRYAATNRLGSHRS Rv2630 32 MLHRDDHINPPRPRGLDVPCARLRATNPLRALARCVQAGKPGTSSGHRSV PHTADLRIEAWAPTRDGCIRQAVLGTVESFLDLESAHAVHTRLRRLTADR DDDLLVAVLEEVIYLLDTVGETPVDLRLRDVDGGVDVTFATTDASTLVQV GAVPKAVSLNELRFSQGRHGWRCAVTLDV Rv2659c 33 VTQTGKRQRRKFGRIRQFNSGRWQASYTGPDGRVYIAPKTFNAKIDAEAW LTDRRREIDRQLWSPASGQEDRPGAPFGEYAEGWLKQRGIKDRTRAHYRK LLDNHILATFADTDLRDITPAAVRRWYATTAVGTPTMRAHSYSLLRAIMQ TALADDLIDSNPCRISGASTARRVHKIRPATLDELETITKAMPDPYQAFV LMAAWLAMRYGELTELRRKDIDLHGEVARVRRAVVRVGEGFKVTTPKSDA GVRDISIPPHLIPAIEDHLHKHVNPGRESLLFPSVNDPNRHLAPSALYRM FYKARKAAGRPDLRVHDLRHSGAVLAASTGATLAELMQRLGHSTAGAALR YQHAAKGRDREIAALLSKLAENQEM Rv2780 34 MRVGIPTETKNNEFRVAITPAGVAELTRRGHEVLIQAGAGEGSAITDADF KAAGAQLVGTADQVWADADLLLKVKEPIAAEYGRLRHGQILFTFLHLAAS RACTDALLDSGTTSIAYETVQTADGALPLLAPMSEVAGRLAAQVGAYHLM RTQGGRGVLMGGVPGVEPADVVVIGAGTAGYNAARIANGMGATVTVLDIN IDKLRQLDAEFCGRIHTRYSSAYELEGAVKRADLVIGAVLVPGAKAPKLV SNSLVAHMKPGAVLVDIAIDQGGCFEGSRPTTYDHPTFAVHDTLFYCVAN MPASVPKTSTYALTNATMPYVLELADHGWRAACRSNPALAKGLSTHEGAL LSERVATDLGVPFTEPASVLA Rv3126c 35 MVIRFDQIGSLVLSMKSLASLSFQRCLRENSSLVAALDRLDAAVDELSAL SFDALTTPERDRARRDRDHHPWSRSRSQLSPRMAHGAVHQCQWPKAVWAV IDNP Rv3127 36 VLKNAVLLACRAPSVHNSQPWRWVAESGSEHTTVHLFVNRHRTVPATDHS GRQAIISCGAVLDHLRIAMTAAHWQANITRFPQPNQPDQLATVEFSPIDH VTAGQRNRAQAILQRRTDRLPFDSPMYWHLFEPALRDAVDKDVAMLDVVS DDQRTRLVVASQLSEVLRRDDPYYHAELEWWTSPFVLAHGVPPDTLASDA ERLRVDLGRDFPVRSYQNRRAELADDRSKVLVLSTPSDTRADALRCGEVL STILLECTMAGMATCTLTHLIESSDSRDIVRGLTRQRGEPQALIRVGIAP PLAAVPAPTPRRPLDSVLQIRQTPEKGRNASDRNARETGWFSPP Rv3128c 37 VWSASGGQCGKYLAASMVLQLDGLERHGVLEFGRDRYGPEVREELLAMSA ASIDRYLKTAKAKDQISGVSTTKPSPLLRNSIKVRRAGDEVEAEPGFFEG DTVAHCGPTLKGEFAHTLNLTDVHIGWVFTRTVRNNARTHILAGLKASVT EIPHGITGLDFDNGTVFLNKPVISWAGDNGIYFTRFRPYKKNH*ATIESK NNHLVRKYAFYYRYDTAEERAVLNRMWKLVNDRLNYLTPTIKPIGYASSA DGRRRRLYDAPQTPLDRPLAARVLSAAQQADLITYRDSLNPAQIGRKIAD LQNRLLILAKEKTEQLYLANIPTALPDIHKGILIKAG Rv3129 38 VVQGRTVLFRTAEGAKLFSAVAKCAVAFEADDHNVAEGWSVIVKVRAQVL TTDAGVREAERAQLLPWTATLKRHCVRVIPWEITGRHFRFGPEPDRSQTF ACEASSHNQR Rv3130c 39 MNHLTTLDAGFLKAEDVDRHVSLAIGALAVIEGPAPDQEAFLSSLAQRLR PCTRFGQRLRLRPFDLGAPKWVDDPDFDLGRHVWRIALPRPGNEDQLFEL IADLMARRLDRGRPLWEVWVIEGLADSKWAILTKLHHCMADGIAATHLLA GLSDESMSDSFASNIHTTMQSQSASVRRGGFRVNPSEALTASTAVMAGIV RAAKGASEIAAGVLSPAASSLNGPISDLRRYSAAKVPLADVEQVCRKFDV TINDVALAAITESYRNVLIQRGERPRFDSLRTLVPVSTRSNSALSKTDNR VSLMLPNLPVDQENPLQRLRIVHSRLTRAKAGGQRQFGNTLMAIANRLPF PMTAWAVGLLMRLPQRGVVTVATNVPGPRRPLQIMGRRVLDLYPVSPIAM QLRTSVAMLSYADDLYFGILADYDVVADAGQLARGIEDAVARLVAISKRR KVTRRRGALSLVV Rv3131 40 MNTHFPDAETVRTVLTLAVRAPSIHNTQPWRWRVCPTSLELFSRPDMQLR STDPDGRELILSCGVALHHCVVALASLGWQAKVNRFPDPKDRCHLATIGV QPLVPDQADVALAAAIPRRRTDRRAYSCWPVPGGDIALMAARAARGGVML RQVSALDRMKAIVAQAVLDHVTDEEYLRELTIWSGRYGSVAGVPARNEPP SDPSAPIPGRLFAGPGLSQPSDVLPADDGAAILALGTETDDRLARLRAGE AASIVLLTATAMGLACCPITEPLEIAKTRDAVRAEVFGAGGYPQMLLRVG WAPINADPLPPTPRRELSQVVEWPEELLRQRC Rv3132 41 MTTGGLVDENDGAAMRPLRHTLSQLRLHELLVEVQDRVEQIVEGRDRLDG LVEAMLVVTAGLDLEATLRAIVHSATSLVDARYGAMEVHDRQHRVLHFVY EGIDEETVRRIGHLPKGLGVIGLLIEDPKPLRLDDVSAHPASIGFPPYHP PMRTFLGVPVRVRDESFGTLYLTDKTNGQPFSDDDEVLVQALAAAAGIAV ANARLYQQAKARQSWIEATRDIATELLSGTEPATVFRLVAAEALKLTAAD AALVAVPVDEDMPAADVGELLVIETVGSAVASIVGRTIPVAGAVLREVFV NGIPRRVDRVDLEGLDELADAGPALLLPLRARGTVAGVVVVLSQGGPGAF TDEQLEMMAAFADQAALAWQLATSQRRMRELDVLTDRDRIARDLHDHVIQ RLFAIGLALQGAVPHERNPEVQQRLSDVVDDLQDVIQEIRTTIYDLHGAS QGITRLRQRIDAAVAQFADSGLRTSVQFVGPLSVVDSALADQAEAVVREA VSNAVRHAKASTLTVRVKVDDDLCIEVTDNGRGLPDEFTGSGLTNLRQRA EQAGGEFTLASVPGASGTVLRWSAPLSQ Rv3134c 42 MSDPRPARAVVVGIDGSRAATHAALWAVDEAVNRDIPLRLVYVIDPSQLS AAGEGGGQSAARAALHDASRKVEATGQPVKIETEVLCGRPLTKLMQESRS AAMLCVGSVGLDHVRGRRGSVAATLAGSALCPVAVIHPSPAEPATTSQVS AVVAEVDNGVVLRHAFEEARLRGVPLRAVAVHAAETPDDVEQGSRLAHVH LSRRLAHWTRLYPEVRVDRAIAGGSACRHLAANAKPGQLFVADSHSAHEL CGAYQPGCAVLTVRSANL Rv3841 43 MTEYEGPKTKFHALMQEQIHNEFTAAQQYVAIAVYFDSEDLPQLAKHFYS QAVEERNHAMMLVQHLLDRDLRVEIPGVDTVRNQFDRPREALALALDQER TVTDQVGRLTAVARDEGDFLGEQFMQWFLQEQIEEVALMATLVRVADRAG ANLFELENFVAREVDVAPAASGAPHAAGGRL Rv3842c 44 MTWADEVLAGHPFVVAHRGASAARPEHTLAAYDLALKEGADGVECDVRLT RDGHLVCVHDRRLDRTSTGAGLVSTMTLAQLRELEYGAWHDSWRPDGSHG DTSLLTLDALVSLVLDWHRPVKIFVETKHPVRYGSLVENKLLALLHRFGI AAPASADRSRAVVMSFSAAAVWRIRRAAPLLPTVLLGKTPRYLTSSAATA VGATAVGPSLPALKEYPQLVDRSAAQGRAVYCWNVDEYEDIDFCREVGVA WIGTHHPGRTKAWLEDGRANGTTR Rv3908 45 VSDGEQAKSRRRRGRRRGRRAAATAENHMDAQPAGDATPTPATAKRSRSR SPRRGSTRMRTVHETSAGGLVIDGIDGPRDAQVAALIGRVDRRGRLLWSL PKGHIELGETAEQTAIREVAEETGIRGSVLAALGRIDYWFVTDGRRVHKT VHHYLMRFLGGELSDEDLEVAEVAWVPIRELPSRLAYADERRLAEVADEL IDKLQSDGPAALPPLPPSSPRRRPQTHSRARHADDSAPGQHNGPGPGP

TABLE 2 DNA sequences of selected low oxygen induced antigens SEQ ID Rv no. NO: Sequence Rv0079 46 gtggaaccgaaacgcagtcgcctcgtcgtatgtgcacccgagccatcgca cgcgcgggaattcccggatgtcgccgtattctccggcggccgggctaacg catcccaggccgaacggttggctcgtgccgtgggtcgcgtgttggccgat cggggcgtcaccgggggtgctcgggtgcggctgaccatggcgaactgcgc cgatgggccgacgctggtgcagataaacctgcaggtaggtgacaccccat taagggcgcaggccgccaccgcgggcatcgatgatctgcgacccgcactg atcagactggatcgacagatcgtgcgggcgtcggcacagtggtgcccccg gccttggccggatcggccccgccggcgattgaccacgccggccgaggcgc tagtcacccgccgcaaaccggtcgtgctaaggcgcgcaaccccgttgcag gcgattgccgctatggacgccatggactacgacgtgcatttgttcaccga cgccgagacgggggaggacgctgtggtctatcgggctggaccgtcggggc tgcggctggcccgccagcaccacgtatttcccccaggatggtcacgttgt cgcgccccagccgggccgccggtgccgctgattgtgaattcgcgtccgac accggttctcacggaggccgccgcggtggaccgggcgcgcgaacatggac tgccattcctgtttttcaccgaccaggccaccggccgcggccagctgctc tactcccgctacgacggcaacctcgggttgatcaccccgaccggtgacgg cgttgccgacggtctggca Rv0080 47 atgagcccgggctcgcggcgcgccagcccgcaaagcgcccgggaggtggt cgagctcgaccgtgacgaggcgatgcggttgctggccagcgttgaccatg ggcgtgtggtgttcacccgcgcggcgctgccggcgatccgtccagtcaat cacctcgtggtcgacggtcgggtgatcgggcgcacccgcctgacggccaa ggtgtccgttgcggtgcgatcgagcgccgatgccggtgtcgtggtcgcct acgaagccgacgaccttgatccgcggcgtcggacggggtggagtgtggtg gtgacgggactggcgaccgaggtcagcgatcccgagcaggttgcccgcta ccagcggctgctacacccgtgggtgaacatggcgatggacaccgtggtcg cgatcgaacccgagatcgtcaccggcatccgcatcgttgctgactcgcgt acgccg Rv0081 48 gtggagtccgaaccgctgtacaagctcaaggcggagttcttcaaaaccct tgcgcatccggcgcggatcaggattttggagctgctggtcgagcgggacc gttcggtcggtgagttgctgtcctcggacgtcggcctggagtcgtcgaac ctgtcccagcagctgggtgtgctacgccgggcgggtgttgtcgcggcacg tcgtgacggcaacgcgatgatctattcgattgccgcacccgatatcgccg agctgctggcggtggcacgcaaggtgctggccagggtgctcagcgaccgg gtggcggtgctagaggacctccgcgccggcggctcggccacg Rv0363c 49 atgcctatcgcaacgcccgaggtctacgcggagatgctcggtcaggccaa acaaaactcgtacgctttcccggctatcaactgcacctcctcggaaaccg tcaacgccgcgatcaaaggtttcgccgacgccggcagtgacggaatcatc cagttctcgaccggtggcgcagaattcggctccggcctcggggtcaaaga catggtgaccggtgcggtcgccttggcggagttcacccacgttatcgcgg ccaagtacccggtcaacgtggcgctgcacaccgaccactgccccaaggac aagttggacagccatgtccggcccttgctggcgatctcggcgcaacgcgt gagcaaaggtggcaatcctttgttccagtcgcacatgtgggacggctcgg cagtgccaatcgatgagaacctggccatcgcccaggagctgctcaaggcg gcggcggccgccaagatcattctggagatcgagatcggcgtcgtcggcgg cgaagaggacggcgtggcgaacgagatcaacgagaagctgtacaccagcc cggaggacttcgagaaaaccatcgaggcgctgggcgccggtgagcacggc aaatacctgctggccgcgacgttcggcaacgtgcatggcgtctacaagcc cggcaacgtcaagcttcgccccgacatccttgcgcaagggcaacaggtgg cggcggccaagctcggactgccggccgacgccaagccgttcgacttcgtg ttccacggcggctcgggttcgcttaagtcggagatcgaggaggcgctgcg ctacggcgtggtgaagatgaacgtcgacaccgacacccagtacgcgttca cccgcccgatcgccggtcacatgttcaccaactacgacggagtgctcaag gtcgatggcgaggtgggtgtcaagaaggtctacgacccgcgcagctacct caagaaggccgaagcttcgatgagccagcgggtcgttcaggcgtgcaatg acctgcactgcgccggaaagtccctaacccac Rv0572c 50 atgggtgagcacgccatcaagcggcacatgcggcaacggaagcctacgaa gcatcccctagcccagaaacggggcgcgcggattctggtcttcaccgacg atccccgcaggagcgtcctcatagtgcccggttgccacctggattccatg cgccgagaaaagaacgcgtactacttccaggacggcaatgcgttggttgg gatggttgtctcgggcggcacggttgagtacgacgccgacgaccgcacat atgtcgtgcagctcaccgacggaaggcacaccactgagtcatctttcgaa cactcatcgccgagtcgatcacctcaatccgatgaccta Rv0574c 51 gtggctggcaatcctgatgtggtgacggtgctgctgggcggtgacgtcat gctcggccgtggcgtcgatcagatcctgcctcatcccggcaaaccgcaat tgcgcgaacggtatatgcgggatgcgaccggctatgttcgcctggccgag cgggtgaacgggcgcattccgctccccgtggattggcgctggccctgggg cgaggcgttggcggtccttgagaacaccgcgaccgacgtctgtttgatca atctggagacgacgatcaccgccgacggtgaattcgccgaccgcaaaccg gtctgctaccggatgcacccggataacgtgccggcgctgacggcattgcg gccgcacgtgtgcgcgctggccaacaaccacattctcgatttcggctacc aggggctgaccgatacggtcgcggctctcgccggtgcggggatccagagt gtcggggcgggagccgatttgctcgccgctcgccgctcggcgctagtcac ggttggccatgaacgccgggtgatcgtcggctcggtagcggcggaatcca gcggcgtccccgaatcctgggccgcccgccgcgaccggcccggagtgtgg ttgatccgggatccggcgcaacgcgacgtcgccgacgatgtggcggcaca ggtgctggcggacaaacgccccggcgatatcgccatagtctcgatgcatt ggggatccaattggggctatgcgaccgcacccggcgacgtcgcgttcgcg caccgactgatcgacgccggcatcgacatggtccacggacattcctcgca ccatccgcggccaatcgagatatatcgcggtaaaccgatcctgtacggat gcggtgacgtcgttgacgactacgaaggcatcggcgggcacgagtcgttc cgcagtgaactgcgactgctgtatctgaccgtcaccgatcccgccagcgg gaacctgatctcgctgcagatgcttccactgcgagtgtcgcggatgcgcc tacagcgtgcctcccagaccgacaccgaatggctccgcaacaccaccgag cgcatcagccgccggttcgggattcgagtcgtgactcgacccgacaacct gctggaggtcgttcccgctgccaacctaacgagcaaggag Rv1264 52 gtgacagaccacgtgcgcgaggcggacgacgcgaacatcgacgatctgtt gggcgacctgggcggtaccgcgcgcgccgagcgtgcgaagcttgtcgagt ggttgctcgagcagggcatcacccccgacgagattcgggcgaccaacccg ccgttgctgctggccacccgccacctcgtcggcgacgacggcacctacgt atccgcaagggagattagcgagaactatggcgttgacctcgagctgctgc agcgggtgcagcgcgctgtcggtctggccagagtggatgatcctgacgcg gtggtgcacatgcgtgccgacggtgaggcggccgcacgcgcacagcggtt cgttgagctggggctgaatcccgaccaagtcgtgctggtcgtgcgtgtgc tcgccgagggcttgtcacacgccgccgaggccatgcgctacaccgcgctg gaggccattatgcggccgggggctaccgagttggacatcgcgaaggggtc gcaggcgctggtgagccagatcgtgccgctgctggggccgatgatccagg acatgctgttcatgcagctgcggcacatgatggagacggaggccgtcaac gccggagagcgtgcggccggcaagccgctaccgggagcgcgacaggtcac cgttgccttcgccgacctggtcggtttcacccagctaggcgaagtggtgt cggccgaagagctagggcacctcgccgggcggctggccggcctcgcgcgt gacctgaccgctccgccggtgtggttcattaagacgatcggcgacgcggt catgttggtctgtcctgatccggcgccattgctggacaccgtgctgaagc tggtcgaggtcgtcgacaccgacaacaactttccccggctgcgagccggc gtcgcctccgggatggcggttagccgggccggcgactggttcggcagccc ggtcaacgtggcaagccgggtgaccggggtggcgcgcccgggtgccgtgc tggtcgcggattcggtgcgggaggcccttggtgatgcccccgaagccgac ggatttcagtggtccttcgccggcccccgtcgcctcaggggaatccgggg tgacgtcaggctttttcgagtccggcgaggggccactcgcaccggctccg gcggcgcggcccaagacgacgatttggccggctcgtcaccg Rv1592c 53 atggtagagcccggcaatttggcaggcgcgaccggcgccgaatggatcgg ccggccaccgcacgaggaattgcagcgcaaagtgcgcccgctgctgccat ccgacgatccgttctacttcccacctgccggctaccagcatgccgtgccc ggaacggtgttgcgctcgcgcgatgtcgaactggcgtttatgggcttgat tccgcagcccgtcaccgctacccagctgctgtaccggaccacgaacatgt acggcaaccccgaggcgacggtgaccacggtgatcgtcccagcggagctt gccccgggtcagacctgccccttgctgtcgtaccagtgtgcgatcgatgc catgtcgtcgcgctgttttccgtcatatgccctgcgacgacgggccaagg ccctggggtcactgacccaaatggagctgttgatgatcagcgccgcactt gccgaaggatgggcggtatcagtacccgaccatgaagggccgaaagggct gtgggggtcgccgtatgaacccggttaccgagtcctcgacggaatccggg ctgccttgaattccgagcgtgtcgggttgtccccggcaacgccgatcggg ctgtggggctactccggcggcgggctggccagcgcgtgggccgccgaagc atgcggcgagtacgcaccggacctagacatcgtcggcgccgtgctgggat cacccgtcggtgaccttggtcacacgttccgccggctcaatggcactctt cttgccggtctgcccgcgttggtggtggccgcgctgcaacacagctaccc cggcctggcccgggtgatcaaggagcacgccaacgacgaaggacgtcagc tgctggagcaactgacggagatgacaacggtagacgcagtgatccggatg gccggcagggacatgggtgacttcctcgacgaaccccttgaggacattct gtcgacgccggaaatttcccatgtcttcggcgacaccaagctgggtagcg cggtgcccaccccgccggtattgatcgtgcaggccgtgcatgactacctc atcgacgtctctgacatcgacgcgctcgctgacagctatacagccggcgg cgccaacgtcacctaccaccgcgacctgttcagcgaacatgtgtccctgc acccgctgtcggccccaatgacgcttcgctggctcaccgaccggttcgcc ggcaagccactgaccgaccaccgcgtccggaccacgtggccgaccatctt caacccgatgacctacgccggcatggcgagactggccgtgatcgcggcca aggtgatcaccggcaggaagttgagccgccgtccgctc Rv1733c 54 atgatcgccacaacccgcgatcgtgaaggagccaccatgatcacgtttag gctgcgcttgccgtgccggacgatactgcgggtgttcagccgcaatccgc tggtgcgtgggacggatcgactcgaggcggtcgtcatgctgctggccgtc acggtctcgctgctgactatcccgttcgccgccgcggccggcaccgcagt ccaggattcccgcagccacgtctatgcccaccaggcccagacccgccatc ccgcaaccgcgaccgtgatcgatcacgagggggtgatcgacagcaacacg accgccacgtcagcgccgccgcgcacgaagatcaccgtgcctgcccgatg ggtcgtgaacggaatagaacgcagcggtgaggtcaacgcgaagccgggaa ccaaatccggtgaccgcgtcggcatttgggtcgacagtgccggtcagctg gtcgatgaaccagctccgccggcccgtgccattgcggatgcggccctggc cgccttgggactctggttgagcgtcgccgcggttgcgggcgccctgctgg cgctcactcgggcgattctgatccgcgttcgcaacgccagttggcaacac gacatcgacagcctgttctgcacgcagcgg Rv1734c 55 atgaccaacgtcggtgaccagggggttgacgcggtcttcggggtgatcta cccacctcaggtcgcgctggtcagtttcggcaagccggcacaacgagttt gcgccgtcgacggcgcgatccacgtcatgacgaccgtgctggctacgctg cccgctgaccacggctgcagcgatgaccatcgcggcgcgctgttcttcct gtcgatcaacgagctgacgcggtgcgccgcagtaacagga Rv1736c 56 gtgacggtgacaccacggaccggcagccgcatcgaggagctgcttgcacg cagcggccggttcttcatcccgggtgagatctcggcggatctgcgtaccg tgacccgccgcggcggccgcgacggcgacgtgttctatcgagaccggtgg agccacgacaaggtggtccgctccacacacggggtgaattgcaccgggtc gtgttcttggaagatctacgtcaaagacgacatcatcacctgggagacgc aggagaccgactatccgtcggtgggcccggaccggcccgagtatgagccc cgcggctgcccgcgcggcgcggcgttttcctggtacacgtattcgccgac gcgggtgcgccatccgtacgcccgcggcgtgcttgtcgagacgtatcggg aggcgaaggcacgtttgggtgatccggtggcggcctgggccgacatccag gccgacccgcggcggcgccgccgctaccagcgcgcccgcggcaagggcgg gctggtccgggtcagctgggccgaggccaccgagatgatcgccgccgccc acgtgcacaccatctccacatacggcccggaccgggttgccggcttctcc cccatcccggcgatgtccatggtgagccacgccgcggggtcgcggttcgt ggagctaatcggcggggtgatgacgtcgttctacgactggtacgccgacc tgccggtggcctccccgcaggtgttcggcgaccagaccgacgtgccggag tccggagattggtgggacgtggtgtggcaatgcgcctcggtgctgctgac ctacccgaactcacggcaactcggcaccgcagaggaattgctggcccaca tcgacggtccggccgcggatctgttggggcgcacggtctctgagctgcgc cgtgccgatccgctgaccgcggcgacccgctacgtcgacaccttcgacct gcgaggccgcgccaccctgtacctgacctactggaccgccggcgacaccc gcaaccgcggccgggagatgctggccttcgcccagacctaccgcagcacc gacgtcgcaccaccgcgcggcgagaccccggacttcctgccggtggtgct cgaattcgccgcgaccgtcgaccccgaggcggggcgacggttgctgagcg ggtaccgggtgcccatcgccgcgctgtgcaatgccctgaccgaggccgca ttgccatacgcacacacggtggccgcggtatgccggacgggtgacatgat gggcgaactcttctggaccgtcgtgccgtatgtgacgatgacgatcgtcg cggtcggctcctggtggcgctaccgctatgacaaattcggctggaccacc cgctcgtcccagctgtacgagtcgcggctgctgcggatcgccagcccgat gtttcatttcggcatcctggtggtcatcgtcggccacggtatcgggctcg tgatcccgcagtcgtggactcaggccgccggtttgagcgagggcgcatat cacgtgcaggccgtcgtgctggggtcgatcgccggcatcaccaccttggc cggcgttaccctgctgatctaccggcggcgcacccgcgggccggtgttca tggctaccaccgtcaacgacaaggtgatgtacctcgtgctggtggcggcg atcgtcgcgggactgggtgcgacggcgttgggctccggcgttgtcggcga ggcgtacaactaccgcgagacggtgtcggtgtggttccgctcggtgtggg tactgcaaccgcgcggggacctgatggccgaggctccgctgtattaccag atccatgtgctgatcgggttggcgttgttcgcgttgtggccgttcacccg gctggtacacgcgttcagcgccccgatcggctatctgttccgcccgtaca tcatctaccgcagccgcgaggagctggtgctaacgcggccgcggcggcgc gggtgg Rv1737c 57 atgagagggcaagcggccaatctcgtgctggccacctggatctcggtggt caacttctgggcgtggaacctgatcggcccgctgtcgaccagctacgcgc gtgacatgtcactgtccagcgccgaggcgtcgctgctcgtcgccaccccg atcctggtgggtgcccttggccgcatcgtcaccgggccgctcaccgaccg cttcggcgggcgcgccatgctcatcgcggtgacgctggcgtcgatcctcc cggcgctcgcggtcggggtcgcggcaaccatgggctcctacgcgttgctg gtgtttttcgggctcttcctgggcgttgccggcacgatcttcgccgtcgg catcccgttcgccaacaactggtaccagccggcgcggcgcggtttctcca ccggcgtgttcggtatgggcatggtcggcaccgcgctctcggcgttcttc accccgcggtttgtacggtggttcggcctgttcaccacccacgccatcgt cgcggccgcgctcgcgtcgaccgccgtggtggccatggtcgtgcttcgtg atgcaccctactttcggcccaacgccgacccggtgctgcccaggctcaag gccgcggcacggttgccggtgacctgggagatgtcgtttctgtacgcgat cgtgttcggcgggttcgtggcgttcagcaactacctgcccacctacatca ccacgatctacgggttctccacggtcgacgcgggcgctcgcaccgccggg ttcgccctggcggcggtgctggcccggccggtgggcgggtggctctccga ccggatcgcaccgaggcacgtggtgctggcctcgctcgccgggaccgcgc tgctggcgttcgccgcggcgttgcagccgccgccggaggtgtggtcggcg gccaccttcatcaccctggcggtctgcctcggcgtgggcaccggcggcgt gttcgcgtgggtggcccgccgcgccccggccgcatcggtcggctcggtca ccggaatcgtcgccgcggcaggcggattgggcggttacttcccgccgctg gtgatgggcgcgacctacgacccggtcgacaacgactacacggtcgggtt gctgctgctggtggcgaccgcgctggtcgcgtgtacctacaccgcgctgc acgcgcgggagccggtgagtgaggaggcgtccagg Rv1738 58 atgtgcggcgaccagtcggatcacgtgctgcagcactggaccgtcgacat atcgatcgacgaacacgaaggattgactcgggcgaaggcacggctgcgtt ggcgggaaaaggaattggtgggtgttggcctggcaaggctcaatccggcc gaccgcaacgtccccgagatcggcgatgaactctcggtcgcccgagcctt gtccgacttggggaagcgaatgttgaaggtgtcgacccacgacatcgaag ctgttacccatcagccggcgcgattgttgtat Rv1739c 59 atgattcccacgatgacatcggccggctgggcaccaggggtggtgcagtt ccgcgaataccaacggcgttggctgcgcggcgatgtcctcgccggcctga ccgtggccgcctatctgatcccgcaagcgatggcgtatgcgaccgtggcg ggcctaccgccggcagccgggctgtgggcgtcgatcgcgccgcttgccat ttacgcactgctcggatcgtcccggcagctttcaatcggcccggaatccg ccaccgccttgatgacggcggccgtgctcgctccgatggccgccggggat cttcgacgctatgccgttctggcggcaaccctcggattgctagtcggcct tatctgcctactcgctggcacggcgcgactaggtttcctcgccagcctgc gatcgcggccggtgctcgtcggatacatggccggcatcgcgcttgtcatg atctccagccaactcggcactatcaccggcacctcggtcgaaggcaacga attcttcagcgaagtacactctttcgcgactagcgtcacgcgagttcact ggccgacttttgtgttagccatgtctgtcctagcgctgctaactatgctc acgcggtgggcgccgcgcgcccccggaccgatcatcgcggttcttgcggc cacgatgctagtggccgttatgtccttggatgccaaaggtattgcgattg tgggtcggataccttccggtctgccgacgccgggtgtgccgcccgtttcg gtggaagacttgcgggcactgatcattccggctgccgggatcgcgattgt taccttcaccgacggtgtgttgaccgcacgcgccttcgccgctcgtcgag gtcaggaagtcaatgccaacgccgagctgcgcgcggtcggggcctgcaac atcgccgccgggctgacacacggttttccggtgagttccagcagcagccg taccgccctcgccgacgtcgtcggtggccgcacccagctgtactcgctga tcgcgttggggcctgttgtcatcgtgatggttttcgcgagtgggctgctg gccatgtttccgatcgccgctctgggcgctttggtggtatatgccgcgct acgcttgatcgacttgtcagaattccggcgactggcgcggtttcggcgca gcgaactcatgctggcactagccaccacagcagccgtgttaggcctagga gtgttctatggagtcctcgccgcggttgccctgtccatcctcgaactgct tcgtcgggtcgcacatccgcatgacagcgttctcgggttcgtgccgggca ttgccggcatgcacgacatcgatgactatccgcaggccaagcgcgtgccc gggctggtggtgtatcgctatgacgcgccgttgtgcttcgccaatgccga agacttccgcaggcgagcactgaccgtggtcgatcaggatccggggcaag tcgagtggttcgtactcaacgccgaatccaatgtggaggtcgacctgact gcgctggatgcgctcgaccaactccgcaccgagctgctgcgtcggggaat agtgttcgccatggcccgggtcaaacaagacttgcgtgaatcactcaggg ccgccagtcttctcgataagattggcgaagaccatatctttatgacattg cctaccgcagtgcaggcgttccgtcggcgc Rv1813c 60 atgatcacaaacctccgacgccgaaccgcgatggcagccgccggcctagg ggctgctctcgggctgggcatcctgctggttccgacggtggacgcccatc tcgccaacggttcgatgtcggaagtcatgatgtcggaaattgccgggttg cctatccctccgattatccattacggggcgattgcctatgcccccagcgg cgcgtcgggcaaagcgtggcaccagcgcacaccggcgcgagcagagcaag tcgcactagaaaagtgcggtgacaagacttgcaaagtggttagtcgcttc accaggtgcggcgcggtcgcctacaacggctcgaaataccaaggcggaac cggactcacgcgccgcgcggcagaagacgacgccgtgaaccgactcgaag gcgggcggatcgtcaactgggcgtgcaac Rv1997 61 ttgtcggcgtcagtgtctgccacgacggctcatcatggcttgccagcaca tgaagtggtgctgctgctggagagcgatccatatcacgggctgtccgacg gcgaggccgcccaacgactagaacgcttcgggcccaacaccttggcggtg gtaacgcgcgctagcttgctggcccgcatcctgcggcagtttcatcaccc gctgatctacgttctgctcgttgccgggacgatcaccgccggtcttaagg aattcgttgacgccgcagtgatcttcggtgtggtggtgatcaatgcgatc gtgggtttcattcaagaatccaaggcagaggccgcactgcagggcctgcg ctccatggtgcacacccacgccaaggtggtgcgcgagggtcacgagcaca caatgccatccgaagagctggttcccggtgaccttgtgctgttagcggcc ggtgacaaggttcccgccgatttgcggctggtgcgacagaccggattgag cgtgaacgagtcagcacttaccggcgagtcgacgccggttcacaaggacg aggtggcgttgccggagggcacaccggtcgctgatcgtcgcaatatcgcg tattccggcacattggtaaccgcgggccatggcgccgggatcgtcgtcgc gaccggcgccgaaaccgaactcggtgagattcatcggctcgttggggccg ccgaggttgtcgccacaccgctgaccgcgaagctggcgtggttcagcaag tttctgaccatcgccatcctgggtctggcagcgctcacgttcggcgtggg tttgctgcgccggcaagatgccgtcgaaacgttcaccgctgcgatcgcgc tggcggtcggggcaattcccgaaggtctgcccaccgccgtgaccatcacc ttggccatcggcatggcccggatggccaagcgccgcgcggtcattcgacg tctacccgcggtggaaacgctgggcagcaccacggtcatctgcgccgaca agaccggaacgctgaccgagaatcagatgacggtccagtcgatctggaca ccccacggtgagatccgggcgaccggaacgggctatgcacccgacgtcct cctgtgcgacaccgacgacgcgccggttccggtgaatgccaatgcggccc ttcgctggtcgctgctggccggtgcctgcagcaacgacgccgcactggtt cgcgacggcacacgctggcagatcgtcggcgatcccaccgagggcgcgat gctcgtcgtggccgccaaggccggcttcaacccggagcggctggcgacaa ctctgccgcaagtggcagccataccgttcagttccgagcggcaatacatg gccaccctgcatcgcgacgggacggatcatgtggtgctggccaagggtgc tgtggagcgcatgctcgacctgtgcggcaccgagatgggcgccgacggcg cattgcggccgctggaccgcgccaccgtgttgcgtgccaccgaaatgttg acttcccgggggttgcgggtgctggcaaccgggatgggtgccggcgccgg cactcccgacgacttcgacgaaaacgtgataccaggttcgctggcgctga ccggcctgcaagcgatgagcgatccaccacgagcggccgcggcatcggcg gtggcggcctgccacagtgccggcattgcggtaaaaatgattaccggtga ccacgcgggcaccgccacggcgatcgcaaccgaggtggggttgctcgaca acactgaaccggcggcaggctcggtcctgacgggtgccgagctggccgcg ctgagcgcagaccagtacccggaggccgtggatacagccagcgtgtttgc cagggtctctcccgagcagaagctgcggttggtgcaagcattgcaggcca gggggcacgtcgtcgcgatgaccggcgacggcgtcaacgacgccccggcc ttgcgtcaggccaacattggcgtcgcgatgggccgcggtggcaccgaggt cgccaaggatgccgccgacatggtgttgaccgacgacgacttcgccacca tcgaagccgcggtcgaggaaggccgcggcgtattcgacaatctgaccaag ttcatcacctggacgctgcccaccaacctcggtgagggcctagtgatctt ggccgccatcgctgttggcgtcgccttgccgattctgcccacccaaattc tgtggatcaacatgaccacagcgatcgcgctcggactcatgctcgcgttc gagcccaaggaggccggaatcatgacccggccaccgcgcgaccccgacca accgctgctgaccggctggcttgtcaggcggactcttctggtttccacct tgctcgtcgccagcgcgtggtggctgtttgcatgggagctcgacaatggc gcgggcctgcatgaggcgcgcacggcggcgctgaacctgttcgtcgtcgt cgaggcgttctatctgttcagctgccggtcgctgacccgatcggcctggc ggctcggcatgttcgccaaccgctggatcatcctcggcgtcagtgcgcag gccatcgcgcaattcgcgatcacatatctacccgcgatgaatatggtgtt cgacaccgcgccaatcgatatcggggtgtgggtgcgcatattcgctgtcg cgaccgcaatcacgattgtggtggccaccgacacgctgctgccgagaata cgggcgcaaccgcca Rv1998c 62 atgagtttccacgatcttcatcaccaaggtgttccgttcgtgttgcccaa cgcctgggatgtgccgtcggccctggcctacctcgcggagggcttcacgg ctatcggcacaaccagtttcggggtctcgtccagcggcgggcacccggac gggcaccgcgccactcgcggcgccaacatcgcactggcggccgccctggc accgctgcaatgctacgtcagcgtcgacatcgaggacggatacagcgacg aacccgacgccattgctgagtacgtcgcacaactgtcgacagccggaatc aatatcgaggacagtagcgccgaaaagctcatcgaccccgccctggcagc cgctaaaatcgttgcgatcaaacaacgtaaccccgaggtgttcgtcaacg cccgcgtcgacacctattggttgcgccagcacgccgataccaccagcacg atccagcgcgcacttcgctacgtcgatgccggcgccgacggcgtctttgt cccactggccaacgatcccgacgaacttgctgagctcactcgcaacattc cgtgcccggttaacacgttgcccgtgcccggcttgacgatcgccgacctt ggtgagctcggggtggcccgggtgtcaaccggttcagtgccctacagcgc ggggttgtatgcagcggcccacgcggctcgggccgtgagcgacggagagc agctgccacggtccgtaccgtacgccgaactgcaggcacgcttggttgac tacgagaaccgcacgagtacaacg Rv2003c 63 gtggtcaagcgctctcgggcaacccgactttcgccgagcatctggtccgg atgggaatcacctcagtgtcggtccattcgggcgcgattgctgctacccc ggggtcggtcgcggccgccgaacgccgattgttgctggaatcagctcgcg gtgacgcctgacacccggatgccggcatcgtcggccgccgggcgcgacgc ggcggcctacgacgcctggtatgactcacccaccgggcggccgatcctgg cgaccgaggtcgccgcgttgcggccgctcatcgaggtctttgcccagcca cgcttggaaatcggtgtcggtacaggacgtttcgccgacctgctcggcgt gcggttcggactcgatccatcccgtgatgcgctgatgttcgcacgccggc gcggcgtcctggtcgccaatgccgtcggcgaggcggtccctttcgtcagc cggcacttcggggcggtcctcatggcattcacgctctgtttcgtcaccga cccggccgccatattccgggaaacgcggcgtctgctcgccgacggcggcg gccttgttatcgggttcttgcctcgcgggacaccgtgggccgacctgtac gctctgcgcgcggcccgcggacagccaggctaccgcgacgcccgcttcta caccgcggccgaactcgaacaactgctcgcagactcgggattccgggtca tcgcccgccgctgcacgctgcaccaaccgccgggactcgcccggtacgac atcgaagccgcccatgacggtatccaagccggcgccggcttcgttgctat ctcggcggtcgaccaagcgcacgagcctaaggatgatcacccactcgagt cggaa Rv2005c 64 atgtctaaaccccgcaagcagcacggagttgtcgtcggggtagatggttc gctcgaatcggatgccgccgcctgttggggtgccaccgatgcggcgatga ggaacattccgctgaccgtggtccacgtggtgaacgccgatgtagcgacg tggccgccgatgccgtatccggagacctggggggtttggcaggaggacga gggtcgccagatcgtcgccaacgccgtcaagctcgccaaagaggcggttg gagcggatcgaaagctcagcgtaaagagcgagctcgtattttccacgccg gtacctaccatggttgaaatctccaacgaggcagagatggtggtgttggg cagctcgggccggggagcgctggcccgaggcttgctcggttcggtcagct cgagcctggtgcgacgcgccgggtgcccggtcgcggtcatccacagcgat gatgcggtgatccctgatccgcagcacgctcccgtgctggtgggaatcga cggttcgccggtttcggagcttgcgacggcggtggcatttgacgaggcgt cgcgccgcggcgtcgaactgatcgccgtgcacgcgtggagtgacgtcgaa gtggtggaacttccgggtttggacttctcggctgtacagcaggaagcgga gcttagtctcgccgaacgcttggcaggttggcaagaacgctatcccgatg tgccggtgagccgggttgtcgtttgcgatcgcccggcgcggaagctggtg caaaagtcggcgtccgcccagcttgtcgtcgttggcagtcatggccgagg tggcttgaccggcatgcttctggggtcggtcagtaacgcggtcttacacg ccgcgcgggtgccagtgatcgtggcacggcagtcg Rv2007c 65 gtgacctatgtgatcggtagtgagtgcgtggatgtgatggacaagtcctg tgtgcaggagtgtccggtcgactgtatctatgagggcgcccgaatgctct acatcaaccccgacgagtgcgtggattgtggtgcgtgcaaaccggcctgc cgcgtcgaggcgatctactgggaaggcgatctacccgacgatcaacacca gcatctgggggacaacgccgcctttttccaccaagtcctgccgggccgag tggctccgctgggttcgccgggtggtgccgcagcggcgggcccgatcgga gtcgacacgcctctggtcgcggctatcccggtggagtgccct Rv2028c 66 atgaaccaatcacacaaacccccatcgatcgtcgtcggtattgatggctc gaagccggccgtgcaagccgcactgtgggcggtcgacgaggcagccagcc gtgacatcccgctgcgtctgctgtacgcgatcgaacccgacgatcccggg tacgccgcacacggcgcggcggctcgcaaactcgccgccgccgagaacgc ggtgcgctacgcgttcacagcggtcgaggcggcggaccggccggtcaagg tcgaggtggagatcacccaggagcggccggtcacctcgttgatccgcgct tcggcggctgctgccctggtgtgcgttggcgctatcggcgtgcaccactt ccgaccggagcgggtgggatctaccgcagcggccctggcgttatcggcgc agtgcccagtggcgatcgtgcgaccccaccgggtccccatcggacgcgac gccgcatggatcgtcgtcgaggcggacgggtcgtccgatatcggtgtttt gctgggggcggtgatggccgaagcacggctgcgcgactcgccggttcggg tggtcacctgccggcaatccggagtgggcgataccggggacgacgtccgt gccagcctggaccgctggcttgcccgttggcaaccacggtatcccgatgt gcgggtgcaatcggcggcagtgcacggcgagctgctggattatctggctg ggctgggtcgatcggtacacatggtggtgctcagcgcgagcgaccaggag catgtggagcaacttgtgggagcgccgggcaacgccgtgttgcaggaggc cggctgcaccctgctggtcgtcggtcagcagtatctg Rv2029c 67 atgacggagccagcggcgtgggacgaaggcaagccgcgaatcatcacttt gaccatgaaccccgccttggacatcacgacgagcgtcgacgtggtgcgcc cgaccgagaaaatgcgttgtggcgcacctcgctacgatcccggcggcggc ggtatcaatgtcgcccgcattgtgcatgtcctcggcggttgctcgacagc actgttcccggccggcgggtcgaccgggagcctgctgatggcgctgctcg gtgatgcgggagtgccatttcgcgtcattccgatcgcggcctcgacgcgg gagagcttcacggtcaacgagtccaggaccgccaagcagtatcgtttcgt gcttccggggccgtcgctgaccgtcgcggagcaggagcaatgcctcgacg aactgcgcggtgcggcggcttcggccgcctttgtggtggccagtggcagc ctgccgccaggtgtggctgccgactactatcagcgggttgccgacatctg ccgccgatcgagcactccgctgatcctggatacatctggtggcgggttgc agcacatttcgtccggggtgtttcttctcaaggcgagcgtgcgggaactg cgcgagtgcgtcggatccgaactgctgaccgagcccgaacaactggccgc cgcacacgaactcattgaccgtgggcgcgccgaggtcgtggtggtctcgc ttggatctcagggcgcgctattggccacacgacatgcgagccatcgattt tcgtcgattccgatgaccgcggttagcggtgtcggcgccggcgacgcgat ggtggccgcgattaccgtgggcctcagccgtggctggtcgctcatcaagt ccgttcgcttgggaaacgcggcaggtgcagccatgctgctgacgccaggc accgcggcctgcaatcgcgacgatgtggagaggttcttcgagctggcggc cgaacccaccgaagtcgggcaggatcaatacgtttggcacccgatcgtta acccggaagcctcgcca Rv2030c 68 gtgctgatgaccgcagcggctgatgtcacccggcgctcgccgcggcgcgt gttccgtgaccgccgcgaggccggccgggtgctggcggaattactcgccg cctatcgggaccagccggacgtgattgtgctcggcttggcccggggtggc ctcccggtcgcatgggaggttgccgcggcactgcatgccccgctagacgc cttcgtcgtgcgcaaacttggtgccccggggcatgacgagttcgccgttg gtgcactggccagcggcggccgcgtcgtggtcaatgacgacgtcgtgcgg ggcctgcggatcacaccgcagcaactgcgcgacatcgccgaacgtgaggg tcgggaactgcttcggcgcgagtccgcctaccgcggcgagcgcccgccca ccgatatcaccggcaagacggtcattgtcgtcgatgacggtttggccacc ggcgcaagcatgttcgcggcggtacaggcattgcgcgatgcgcaaccagc gcagatcgtgattgccgtgccggcggcgccggagtccacgtgccgggagt tcgccggcctcgtcgacgacgttgtgtgcgcgaccatgccgaccccgttc ctggccgtcggtgagtcgttttgggacttccggcaggtcaccgacgagga ggtccgccggctcctggccaccccgaccgctgggccgtcgctgcgccggc ccgcggcgtcaacggcggccgatgttctgcgcagagtcgcgatcgacgcc cccgggggtgttccgacgcacgaggtgttggcggagctggtcggcgatgc acgaatcgtgttgatcggcgaaagctcgcacggcacacacgagttctacc aggcccgggccgccatgacacagtggctgatcgaggagaagggctttggt gcggtagccgccgaggcggactggcccgacgcctaccgggtcaatcggta cgttcgcggcctcggcgaggacaccaacgctgacgaggcgcttagcggat tcgagcggtttcccgcctggatgtggcgcaacaccgtggtccgagatttt gtggaatggctgcgcacacgcaaccagcgctacgagtcgggcgcgctgcg gcaagccggcttctacggtctggatctttacagcctgcatcggtcgatcc aagaggtgatcagctatctcgacaaggtcgacccgcgtgcggcggcacgg gcgcgggcccggtatgcgcgcttcgaccatgcctgcgccgatgacggtca ggcgtacggattcgcggccgcattcggcgccggtccgtcgtgcgaacgtg aagccgtcgagcaactggtcgacgttcagcgcaatgccctggcgtatgcg cgccaagacgggctgcttgccgaggacgaactgttctacgcccagcaaaa cgcgcagacggtgcgcgacgcagaggtgtattaccgggccatgttcagtg gacgcgttacctcgtggaacctgcgcgaccagcacatggcgcagaccctt ggcagtttgctgacgcatttggaccgacacctcgatgcgccgccggcgcg aatagtggtgtgggctcataactcccacgtgggtgacgcacgcgctaccg aggtgtgggccgacgggcagctcaccctcggccagatagtccgtgagcga tacggtgacgagtcgcgcagcatcggattcagcacgtacacgggcaccgt caccgcggccagcgaatggggtggtatcgcccaacgcaaagcggttcggc cggcactgcacggcagtgtcgaggagctcttccaccagactgcagacagt ttcctggtgtcagcgcggctaagccgcgacgccgaagccccgctggacgt tgtccggttgggacgtgccatcggcgtcgtttatctaccggcaacggaac ggcaaagtcactacttgcacgtgcggcccgccgaccagttcgacgccatg atccacatcgatcagacccgtgccctggaacctctcgaggtgacgagccg gtggatcgccggcgagaacccggaaacctacccgaccggtctg Rv2031c 69 Atggccaccacccttcccgttcagcgccacccgcggtccctcttccccga gttttctgagctgttcgcggccttcccgtcattcgccggactccggccca ccttcgacacccggttgatgcggctggaagacgagatgaaagaggggcgc tacgaggtacgcgcggagcttcccggggtcgaccccgacaaggacgtcga cattatggtccgcgatggtcagctgaccatcaaggccgagcgcaccgagc agaaggacttcgacggtcgctcggaattcgcgtacggttccttcgttcgc acggtgtcgctgccggtaggtgctgacgaggacgacattaaggccaccta cgacaagggcatccttactgtgtcggtggcggtttcggaagggaagccaa ccgaaaagcacattcagatccggtccaccaac Rv2032 70 atgccggacaccatggtgaccaccgatgtcatcaagagcgcggtgcagtt ggcctgccgcgcaccgtcgctccacaacagccagccctggcgctggatag ccgaggaccacacggttgcgctgttcctcgacaaggatcgggtgctttac gcgaccgaccactccggccgggaagcgctgctggggtgcggcgccgtact cgaccactttcgggtggcgatggcggccgcgggtaccaccgccaatgtgg aacggtttcccaaccccaacgatcctttgcatctggcgtcaattgacttc agcccggccgatttcgtcaccgagggccaccgtctaagggcggatgcgat cctactgcgccgtaccgaccggctgcctttcgccgagccgccggattggg acttggtggagtcgcagttgcgcacgaccgtcaccgccgacacggtgcgc atcgacgtcatcgccgacgatatgcgtcccgaactggcggcggcgtccaa actcaccgaatcgctgcggctctacgattcgtcgtatcatgccgaactct tttggtggacaggggcttttgagacttctgagggcataccgcacagttca ttggtatcggcggccgaaagtgaccgggtcaccttcggacgcgacttccc ggtcgtcgccaacaccgataggcgcccggagtttggccacgaccgctcta aggtcctggtgctctccacctacgacaacgaacgcgccagcctactgcgc tgcggcgagatgctttccgccgtattgcttgacgccaccatggctgggct tgccacctgcacgctgacccacatcaccgaactgcacgccagccgagacc tggtcgcagcgctgattgggcagcccgcaactccgcaagccttggttcgc gtcggtctggccccggagatggaagagccgccaccggcaacgcctcggcg accaatcgatgaagtgtttcacgttcgggctaaggatcaccgg Rv2428 71 atgccactgctaaccattggcgatcaattccccgcctaccagctcaccgc tctcatcggcggtgacctgtccaaggtcgacgccaagcagcccggcgact acttcaccactatcaccagtgacgaacacccaggcaagtggcgggtggtg ttcttttggccgaaagacttcacgttcgtgtgccctaccgagatcgcggc gttcagcaagctcaatgacgagttcgaggaccgcgacgcccagatcctgg gggtttcgattgacagcgaattcgcgcatttccagtggcgtgcacagcac aacgacctcaaaacgttacccttcccgatgctctccgacatcaagcgcga actcagccaagccgcaggtgtcctcaacgccgacggtgtggccgaccgcg tgacctttatcgtcgaccccaacaacgagatccagttcgtctcggccacc gccggttcggtgggacgcaacgtcgatgaggtactgcgagtgctcgacgc cctccagtccgacgagctgtgcgcatgcaactggcgcaagggcgacccga cgctagacgctggcgaactcctcaaggcttcggcc Rv2624c 72 atgtctgggagaggagagccgacgatgaaaacaatcattgttggtatcga tggttcgcacgcggcgattacggccgcattgtggggggttgacgaggcca tcagccgagcggtgccgctgcgactggtctcagtgatcaagccgacacat ccgtccccggacgactacgaccgcgaccttgcgcatgctgaaagatcgct tcgggaagcgcagtccgctgttgaggccgcgggcaagctcgtcaagatcg aaaccgacatcccccgcgggccagccggcccggtgcttgtggaggcatcg cgcgacgccgagatgatctgcgtcggctccgtgggaatcgggcgctacgc cagctcgatcttgggttcgacggcaaccgagctggccgaaaaggcgcatt gcccggtcgccgtcatgcgctcaaaagtggaccagccagcgtctgacatc aactggatcgtggtgcgcatgaccgacgcaccggataacgaggccgtgct ggaatacgctgcccgggaagcgaagttgcggcaagcgcccatactggcac tcggcgggcgaccggaggagctccgggagattccggacggcgaattcgaa cgtcgcgtgcaggattggcaccaccgtcatcccgatgtgcgcgtctaccc gatcaccactcacacgggtattgcccggttcctggccgaccacgacgagc gcgtacagctggcagtgatcggcggtggtgaggccggtcagctagcgcgg ctggtcgggccatccggacatccggtgttccgtcacgccgagtgttcggt gcttgtcgttcgccgc Rv2625c 73 atgcgtgatgcgatcccgcttgggcggatcgccgggtttgtggtgaacgt ccactggagcgtgttggtgatcctgtggttgttcacctggagtctggcga ccatgttgccgggtaccgtcggaggctacccggccgtggtctattggctt ctcggcgcaggtggcgcggtcatgttgctggcgtcgctgttggctcatga gctcgcgcacgccgtcgtcgctcgtcgcgccggggtatccgttgagagcg tgacgttgtggctgttcggcggggtgaccgcgcttggcggcgaggcaaag acgcccaaagccgctttccggatcgcgttcgcgggtccggctaccagcct ggcgctgtcggcgacattcggtgcgttggccatcacgctcgccggcgtgc ggaccccggccatcgtgatcagcgttgcttggtggttggctactgtcaac ctgctgctggggctgttcaatctgctgcctggcgcgccgttggacggtgg gcggttggtccgggcctatctgtggcgccgccacggcgatagtgtgcgcg ccgggatcggtgcggcgcgggccggacgggtggttgcgctggtcttgatc gcgttgggattggccgagtttgtggctggtggcctcgtcggtggggtctg gttagccttcattggctggtttatcttcgctgccgctcgcgaggaggaga cccggatttcgacccagcagctgtttgccggggtgcgtgtggccgatgcg atgaccgcccaaccgcatacggctcccggatggatcaatgtcgaggattt catccagcgttacgtgcttggtgaacggcactcggcatatccggttgccg atcgggacggatcgatcacgggcctggtggcattgcggcagctgcgcgat gttgcgcctagccggcgcagcactaccagcgtaggtgacattgcgctgcc gctgcacagcgtgccgaccgcccgaccacaagagccgctgaccgcgctcc tagagcggatggcaccgctcggcccgcgcagccgtgcgctggtcaccgaa gggagcgcggtggtcggcaccgtcactcccagcgatgtcgcgcggctgac tgacgtctaccggttggcccagccggaaccgacctttaccacgagtcccc aagatgcggacaggttttccgatgcgggg Rv2627c 74 atggcaagttctgcgagcgacggcacccacgaacgctcggcttttcgcct gagtccaccggtcttgagcggcgccatgggaccgttcatgcacaccggtc tgtacgtcgctcaatcgtggcgcgactatctgggtcaacagcccgataaa ctgccgatcgcacggcccactattgccttagcggcgcaagcctttcgaga cgaaatcgtcctgctgggcctcaaggcacgacgtccggtcagcaatcatc gagtgttcgagcgcatcagccaagaagtggccgctggactggagttctat gggaatcgcagatggctggagaagcctagcggattttttgcccagccccc accgctcaccgaggtcgcggtccgaaaggtcaaggaccgcagacgctcct tttatcgcatcttcttcgacagtgggtttacgccgcatccgggtgaaccg ggcagccaacggtggctctcatacactgcgaacaatcgcgagtacgccct gttactgcggcacccagagccgcgtccctggctggtttgtgtacacggca ccgagatgggcagggccccgttggatctcgcggtgttccgcgcctggaag ctgcatgacgaactcggcctgaacattgtcatgccggttcttccgatgca tggtccccgcgggcaaggtctgccgaagggcgccgtttttcccggagaag atgttctcgacgatgtgcatgggacggctcaagcggtgtgggatatccgg cggctgttgtcctggatacgatcgcaggaggaggagtcgctgatcgggtt gaacggtctctcgctgggcggctacatcgcgtcattggtcgccagcctcg aagaaggtctcgcctgcgcgattctcggtgtcccagtggctgatctgatc gagttgttgggccgccactgcggtcttcggcacaaagacccccgccgcca caccgtcaagatggccgaaccgatcggccgaatgatctcgccgctctcac ttacgccactggtgcccatgccgggccgctttatctacgcgggcattgcc gaccgactcgtgcatccacgcgaacaggtgactcgcctctgggagcactg gggcaaacccgaaatcgtgtggtatccaggcggtcacactggcttcttcc agtcgcggccggtacgacggtttgtccaggctgcgctggagcagtcgggc ctgttggacgcgccacggacacagcgcgaccgttccgcc Rv2628 75 Atgtccacgcaacgaccgaggcactccggtattcgggctgttggccccta cgcatgggccggccgatgtggtcggataggcaggtggggggtgcaccagg aggcgatgatgaatctagcgatatggcacccgcgcaaggtgcaatccgcc accatctatcaggtgaccgatcgctcgcacgacgggcgcacagcacgggt gcctggtgacgagatcactagcaccgtgtccggttggttgtcggagttgg gcacccaaagcccgttggccgatgagcttgcgcgtgcggtgcggatcggc gactggcccgctgcgtacgcaatcggtgagcacctgtccgttgagattgc cgttgcggtc Rv2629 76 atgcgatcagaacgtctccggtggctggtagccgcagaaggtccgttcgc ctcggtgtatttcgacgactcgcacgacactcttgatgccgtcgagcgcc gggaagcgacgtggcgcgatgtccggaagcatctcgaaagccgcgacgcg aagcaggagctcatcgacagcctcgaagaggcggtgcgggattctcgacc ggccgtcggccagcgtggccgcgcgctgatcgcgaccggcgagcaagtac tggtcaacgagcatctgatcggcccaccaccggctacggtgattcggctg tcggattatccgtacgtcgtgccattgatagaccttgagatgcggcgacc gacgtatgtatttgccgcggttgatcacaccggcgccgacgtcaagctgt atcagggggccaccatcagttccacgaaaatcgatggggtcggctacccg gtgcacaagccggtcaccgccggctggaacggctacggcgacttccagca caccaccgaagaagccatccgaatgaactgccgcgcggtcgccgaccatc tcacccgactggtagacgctgccgaccccgaggtggtgttcgtgtccggc gaggtgcggtcacgcacagacctgctttccacattgccgcagcgggtggc ggtccgggtgtcgcagctgcatgccggaccgcgcaaaagcgccttagacg aggaagagatctgggacctgacatccgcggagttcacccggcggcggtac gccgaaatcaccaatgtcgcacaacaatttgaggcggagatcggacgcgg atcggggctggcggcccaagggttggcggaggtgtgtgcggctctgcgtg acggcgacgtcgacacgctgatcgtcggagagctaggcgaggccaccgtg gtcaccggtaaagcgcgtactacggtcgcgcgggatgccgacatgttgtc cgaactcggcgaaccggtagatcgcgtggcaagggccgatgaggcgttgc cattcgccgcgatcgcggtaggtgccgcattggtccgtgacgacaaccgg atcgcgccactagatggggtgggcgcattgctgcgttatgccgccaccaa ccgactcggcagccatagatcc RV2630 77 Atgctgcaccgcgacgatcacatcaatccgccgcggccccgcgggttgga tgttccttgcgcccgcctacgagcgacaaatcccctgcgcgccttggcgc gttgcgctcaggcgggcaagccgggcaccagttcagggcatcggtccgtg ccgcatacggcggacttgcgaatcgaagcctgggcaccgacccgtgacgg ctgtatccggcaggcggtgctgggtaccgtcgagagcttcctcgacctgg aatccgcgcacgcggtccatacccggctgcgccggctgaccgcggatcgc gacgacgatctactggtcgcggtgctcgaggaggtcatttatttgctgga caccgtcggtgaaacgcctgtcgatctcaggctgcgcgacgttgacgggg gtgtcgacgtcacattcgcaacgaccgatgcgagtacgctagttcaggtg ggtgccgtgccgaaggcggtgtcactcaacgaacttcggttctcgcaggg tcgccacggctggcgatgtgcggtaacgctcgatgtg Rv2659c 78 Gtgacgcaaaccggcaagcgtcagagacgcaaattcggtcgcatccgaca gttcaactccggccgctggcaagccagctacaccggccccgacggccgcg tgtacatcgcccccaaaaccttcaacgccaagatcgacgccgaagcatgg ctcaccgaccgccgccgcgaaatcgaccgacaactatggtccccggcatc gggtcaggaagaccgccccggagccccattcggtgagtacgccgaaggat ggctgaagcagcgtggaatcaaggaccgcacccgcgcccactatcgcaaa ctgctggacaaccacatcctggccaccttcgctgacaccgacctacgcga catcaccccggccgccgtgcgccgctggtacgccaccaccgccgtgggca caccgaccatgcgggcacactcctacagcttgctgcgcgcaatcatgcag accgccttggccgacgacctgatcgactccaacccctgccgcatctcagg cgcgtccaccgcccgccgcgtccacaagatcaggcccgccaccctcgacg agctggaaaccatcaccaaagccatgcccgacccctaccaggcgttcgtg ctgatggcggcatggctggccatgcgctacggcgagctgaccgaattacg ccgcaaagacatcgacctgcacggcgaggttgcgcgggtgcggcgggctg tcgttcgggtgggcgaaggcttcaaggtgacgacaccgaaaagcgatgcg ggagtgcgcgacataagtatcccgccacatctgatacccgccatcgaaga ccaccttcacaaacacgtcaaccccggccgggagtccctgctgttcccat cggtcaacgaccccaaccgtcacctagcaccctcggcgctgtaccgtatg ttctacaaggcccgaaaagccgccggccgaccagacttacgggtgcacga ccttcgacactccggcgccgtgttggctgcatccaccggcgccacactgg ccgaactgatgcagcggctaggacacagcacagccggcgccgcactccgc taccagcacgccgccaagggccgggaccgcgaaatcgccgcactgttaag caaactggccgagaaccaggagatg Rv2780 79 Atgcgcgtcggtattccgaccgagaccaaaaacaacgaattccgggtggc catcaccccggccggcgtcgcggaactaacccgtcgtggccatgaggtgc tcatccaggcaggtgccggagagggctcggctatcaccgacgcggatttc aaggcggcaggcgcgcaactggtcggcaccgccgaccaggcgtgggccga cgctgatttattgctcaaggtcaaagaaccgatagcggcggaatacggcc gcctgcgacacgggcagatcttgttcacgttcttgcatttggccgcgtca cgtgcttgcaccgatgcgttgttggattccggcaccacgtcaattgccta cgagaccgtccagaccgccgacggcgcactacccctgcttgccccgatga gcgaagtcgccggtcgactcgccgcccaggttggcgcttaccacctgatg cgaacccaagggggccgcggtgtgctgatgggcggggtgcccggcgtcga accggccgacgtcgtggtgatcggcgccggcaccgccggctacaacgcag cccgcatcgccaacggcatgggcgcgaccgttacggttctagacatcaac atcgacaaacttcggcaactcgacgccgagttctgcggccggatccacac tcgctactcatcggcctacgagctcgagggtgccgtcaaacgtgccgacc tggtgattggggccgtcctggtgccaggcgccaaggcacccaaattagtc tcgaattcacttgtcgcgcatatgaaaccaggtgcggtactggtggatat agccatcgaccagggcggctgtttcgaaggctcacgaccgaccacctacg accacccgacgttcgccgtgcacgacacgctgttttactgcgtggcgaac atgcccgcctcggtgccgaagacgtcgacctacgcgctgaccaacgcgac gatgccgtatgtgctcgagcttgccgaccatggctggcgggcggcgtgcc ggtcgaatccggcactagccaaaggtctttcgacgcacgaaggggcgtta ctgtccgaacgggtggccaccgacctgggggtgccgttcaccgagcccgc cagcgtgctggcc Rv3126c 80 Atggtcatccggtttgatcaaatagggtcattggtcctctcaatgaaatc ccttgcgccactgtcgtttcagcggtgtctgcgcgagaattctagcttgg tcgcggcgctggaccggctcgatgctgcggtcgatgagctgagcgctttg tcgtttgatgcgttgaccactccggagcgggatcgcgcccgtcgcgaccg ggaccatcatccttggtcccgctcccgctcgcagttgtcgccacgaatgg cgcacggtgcagtgcaccaatgccagtggccgaaggcggtttgggctgtc attgacaatcca Rv3127 81 Gtgctcaagaacgcagtcttgctggcatgccgggcgccgtcggtgcacaa cagccagccctggcgttgggtggccgaaagcggctccgagcacactactg tgcacctgttcgtcaaccgccaccgaacggtgccggccaccgaccattcc ggccggcaagcgatcatcagttgcggtgccgtactcgatcaccttcgcat cgccatgacggccgcgcactggcaggcgaatatcactcgctttccccagc cgaaccaacctgaccagttggccaccgtcgaattcagtcccatcgatcac gtcacggcgggacagcgaaaccgcgcccaggcgattctgcagcgccgaac cgatcggcttccgtttgacagcccgatgtactggcacctgtttgagcccg cgctgcgcgacgccgtcgacaaagacgttgcgatgcttgatgtggtatcc gacgaccagcgaacacgactggtggtagcgtcacaactcagcgaagtcct gcggcgggacgatccgtactatcacgccgaactcgaatggtggacttcac cgttcgtgctggcccatggtgtgccgccggatacgctggcatcggacgcc gaacgcttgcgggttgacctgggccgtgacttcccggtccggagctacca gaatcgccgtgccgagctagctgatgaccgatcgaaagtccttgtgccgt cgacccctagcgacacgcgagccgacgcactgaggtgtggcgaagtgctg tcgaccatcctactcgagtgcaccacggccggcatggctacctgcacgtt gacccatccgatcgaatccagtgacagtcgtgacatcgtgcggggcctga cgaggcagcgaggcgagccgcaagccttgatccgggtagggatagccccg ccgttggcagcagttcccgcccccacaccacggcggccgctggacagcgt cttgcagattcgccagacgcccgagaaagggcgtaatgcctcagatagaa atgcccgtgaaacgggttggttcagcccgcct Rv3128c 82 gtgtggtccgcctcgggtgggcagtgcgggaagtatcttgccgcctcgat ggtgctgcagcttgatgggttggaacgtcacggtgtgttggagtttgggc gtgaccgctatggccccgaggtgcgtgaggagctgttggcgatgagtgcg gccagcatcgatcgttatctgaagaccgcgaaggccaaagaccagatatc gggtgtgtcgacgacgaaaccctcaccactgctgcgtaattcgatcaagg ttcgcagggccggcgatgaggtcgaggcggagccggggttcttcgagggc gacaccgtcgcccattgcggtccgacgctcaaaggcgagttcgcccacac cctgaacttgaccgacgtgcacatcggatgggtgttcacccgcaccgtcc gcaacaacgcccgtacccacatcctcgccgggctcaaagcttctgtcacc gagatcccgcatgggataacgggtttagatttcgacaacggcaccgtgtt tctcaacaagccggtcatcagctgggccggcgacaacggtatctacttca cccgctttcgcccgtacaagaaaaaccactaggccaccatcgagtccaag aacaaccacctggtccgcaagtacgcgttctactaccgctatgacaccgc cgaggaacgcgccgtgctcaaccggatgtggaagctggtcaacgaccgcc tcaactacctcaccccgaccatcaaaccgatcgggtatgccagcagcgcc gacggccgccgccgacgcctctacgatgccccacagacgccgctggaccg gccactggccgcaagggtgctctccgcggcccagcaggccgacctgatca cctaccgagacagcctcaaccccgcccagatcggccgcaaaatcgccgac ctgcagaaccgactcctcatcttggccaaggagaaaaccgagcagctcta cctcgctaacatccccaccgccctacccgacatccacaaaggcatcctga tcaaggcgggc RV3129 83 Gtggtgcaaggccgcaccgtgctgtttcgtaccgcggagggcgccaaatt attttcagccgtcgcgaagtgcgcggtggctttcgaggcggacgaccaca acgttgccgagggctggagcgtgatcgtcaaggttcgcgcccaggtgctg acgaccgacgcgggggtccgcgaagccgaacgcgcccagttactaccgtg gaccgcgacgctgaaacgtcactgtgtgcgggtgatcccgtgggagatca ccggccgccacttcaggttcggtccggaaccggaccgcagccagaccctt gcctgcgaggcctcgtcacacaaccagcga Rv3130c 84 atgaatcacctaacgacacttgacgccgggtttctcaaggcagaagacgt ggatcggcacgtgagtctggcaatcggcgctctggcggtcatcgaggggc cggctcccgatcaggaagccttcttatcgtcgctcgctcaacgcctacgt ccctgtacccggttcgggcagcggtcacgcctgcgcccgttcgacctcgg tgcacccaaatgggtggacgatcccgacttcgatcttggccgtcatgtgt ggcgcatcgccttgccgcggcctggcaacgaagaccagttattcgagctg atcgccgatctgacggcgcgtcgtttggaccggggtcgaccgctgtggga ggtctgggtcatcgaaggcctggcggacagcaagtgggcgatcctgacca aactgcaccactgcatggccgacggaatcgcggcgactcacctgctagct gggctctccgatgaaagtatgagcgacagcttcgcgagcaacatccacac gaccatgcagtcgcaatccgcatctgtgcggcggggtggattccgtgtca atccaagcgaggcgttgaccgcgtcgaccgccgtgatggcaggcatcgtt cgcgcggccaagggtgccagtgagatcgcggccggcgtgctaagtcccgc cgcgtcgtcgttgaacgggccgatcagtgatttgcgtcgctacagcgcag caaaggtccctctcgccgacgtcgaacaggtgtgccggaaattcgacgtc accatcaatgatgttgcgcttgccgcgattacggaaagctaccgcaacgt cctcatccagcggggtgagcggcctaggtttgattcgctgcgtacgctag tgccggtctcgacgcgttccaacagcgctttgagcaagaccgataaccgt gtttcgttaatgctgcccaacctgccggtggatcaagagaacccgctgca gcggctgcggatcgtgcactcgcggctgactcgggccaaggcggggggac agagacaattcggaaatactttgatggcgattgccaaccgccttccgttc cccatgaccgcatgggcggtcgggctgttgatgcggctgccgcagcgtgg tgttgtcaccgtggcgacaaatgtgccgggtccacgacggccgctgcaga ttatgggcagacgggtgcttgacctatacccggtttcgccgatcgcgatg caactgcgcaccagtgtcgcgatgctcagctacgccgacgacctgtactt cgggatcctggccgactacgacgtggtagcagatgccggccagctggcgc gaggaattgaagacgccgtcgcacggctggtggcgatcagtaagcggcgc aaggtgactcgcaggcgcggagcgctatcgctggttgtg Rv3131 85 atgaacacccatttcccggacgccgaaaccgtgcgaacggttctcaccct ggccgtccgggccccctccatccacaacacgcagccgtggcggtggcggg tatgcccgacgagtctggagctgttctctagacccgatatgcagctgcgt agcaccgatccggacgggcgtgagttgatcctcagctgtggtgtggcatt gcaccactgcgtcgtcgctttggcgtcgctgggctggcaggccaaggtaa accgtttccccgatcccaaggaccgctgccatctggccaccatcggggta caaccgcttgttcccgatcaggccgatgtcgccttggcggcggccatacc gcggcgacgcaccgatcggcgcgcccacagttgctggccggtgccaggag gtgacatcgcgttgatggccgcaagagcagcccgtggcggggtcatgctg cggcaggtcagtgccctagaccgaatgaaagccattgtggcgcaggctgt cttggaccacgtgaccgacgaggaatatctgcgcgagctcaccatttgga gtgggcgctacggttcagtggccggggttcccgcccgcaacgagccgcca tcagaccccagtgccccgatccccggtcgcctgttcgccgggcccggtct gtctcagccgtccgacgtcttacccgctgacgacggcgccgcgatcctgg cactaggcaccgagacagacgaccggttggcccggctgcgcgccggcgag gccgccagcatcgtcttgttgaccgcgacggcaatggggctggcgtgctg cccgatcaccgaaccgctggagatcgccaagacccgcgacgcggtccgtg ccgaggtgttcggcgccggcggctacccccagatgctgctgcgagtgggt tgggcaccgatcaatgccgacccgttgccaccgacgccacggcgcgaact gtcccaggtcgttgagtggccggaagagctactgcgacaacggtgc Rv3132c 86 atgacaacagggggcctcgtcgacgaaaacgacggcgccgcaatgcgtcc actgcgtcacacgctctcccaactacgcctgcacgagctgctggtcgagg tgcaggaccgggtcgagcagatcgtcgagggccgggaccgcctcgatggt ctggtggaggccatgctcgtggtcacagcgggcctggacctggaggcaac cctacgcgctatcgtgcattcagcgaccagccttgtcgatgcgcgctatg gcgctatggaggtgcacgaccggcagcatcgggtattgcactttgtctat gaaggcatcgacgaggagaccgttcggcggatcggccacctaccgaaagg cctaggcgtcatcgggctgctcatcgaagatcccaaaccgttacggctgg acgatgtttctgcgcacccggcctcgattggttttccgccgtatcatccg ccgacgcgtaccttccccggggtaccggttcgggtgcgcgatgaatcgtt cggcactctgtacctgactgacaagaccaacgggcaaccgttcagcgacg acgacgaggttctggtccaggcgctggcggccgccgcgggtatcgcagtc gcgaatgcccggctctaccagcaggctaaggcgcgtcagtcgtggatcga ggccacccgtgacatcgccaccgagttgttgcccggcaccgaacccgcga cggtgttccggcttgtcgccgcggaggcgctcaagctgacggcggctgac gctgccctggtagccgttcccgtcgacgaggacatgcctgccgctgacgt gggggagctgctggtgattgaaacagtcggcagcgctgtggcttccattg ttgggcgaacgattccggtggcgggcgcggtgctgcgggaggtcttcgtc aacggcattccgcgacgggtcgaccgggtcgatttggaaggcctggacga actggccgacgcaggtccggcgctgctgttgccgctgcgggccagaggta ccgtagcgggtgtcgttgttgtgctgagtcaaggcggtccaggggctttc accgacgaacaactcgagatgatggccgcgttcgccgaccaggccgcgct ggcttggcaattggccacttcgcaacgtcggatgcgcgaactcgacgtac tgaccgaccgggatcgtatcgcccgtgacctccatgaccatgtcatccag cggctcttcgcgattggcctggctttgcagggtgctgtcccgcacgaacg taatcctgaagtgcagcaacgactctcggacgtggtagacgatctgcaag acgttatacaggaaatccggaccaccatttatgacctgcacggagcatcg cagggtatcactcggctccggcagcgaatcgatgcggccgtagcccaatt tgccgactcggggttgcgcaccagcgttcaattcgtgggtccattgtcgg tggtcgacagcgcgctcgccgatcaggccgaggcggtggttcgggaagcg gtcagcaacgcggttcgccatgcgaaggccagcacgttgaccgtccgggt caaagtcgacgacgacttgtgcatcgaggtgaccgacaacggccgcgggc tgcccgacgagttcaccggaagcggcttaacgaacctgcggcagcgggca gagcaggccggcggcgaattcaccctcgcgagcgtaccgggcgcgagcgg aacagtgctgcgatggtcagcaccgttgtcgcag Rv3134c 87 atgagcgatcctcggccagctcgggcagtggtcgttggtatcgacgggtc aagggcggcaacgcatgcggcgttgtgggcggtcgatgaggcggtgaacc gagacattccgctgcgactggtgtacgtcatcgatccgtcccaactgtcc gccgccggcgagggcggtgggcaatcagcggcccgagcggcgctgcacga cgcctctcggaaggtcgaggccaccgggcaaccggtcaagatcgaaacgg aggttctgtgcggcaggccgctcaccaagctgatgcaggagtccaggtcc gcggcgatgctgtgcgtcggttcggtggggcttgatcatgtccgcggtcg ccggggttcggtcgcggagaccctggctgggtcggccttatgccccgtgg cggtgattcacccgtcgccggccgagccagcgacaacctcccaggtcagc gcggttgtcgcggaggtggacaatggtgtggtgctgcggcacgcattcga ggaggccaggctgcgcggagttccgctgcgggccgtggctgtccacgctg ctgaaacacccgatgacgtcgaacagggcagccggctggcgcatgtacac ctgagccgtcggctcgcccactggacccggctctaccccgaggtgcgggt ggatcgggccatcgccggcggcagtgcgtgccgtcatctggccgccaacg caaagccgggtcagctgttcgtcgcggactcacactccgcgcacgaattg tgcggtgcataccagcccggatgcgccgtacttacggtacgcagtgccaa cttg RV3841 88 atgacagaatacgaagggcctaagacaaaattccacgcgttaatgcagga acagattcataacgaattcacagcggcacaacaatatgtcgcgatcgcgg tttatttcgacagcgaagacctgccgcagttggcgaagcatttttacagc caagcggtcgaggaacgaaaccatgcaatgatgctcgtgcaacacctgct cgaccgcgaccttcgtgtcgaaattcccggcgtagacacggtgcgaaacc agttcgacagaccccgcgaggcactggcgctggcgctcgatcaggaacgc acagtcaccgaccaggtcggtcggctgacagcggtggcccgcgacgaggg cgatttcctcggcgagcagttcatgcagtggttcttgcaggaacagatcg aagaggtggccttgatggcaaccctggtgcgggttgccgatcgggccggg gccaacctgttcgagctagagaacttcgtcgcacgtgaagtggatgtggc gccggccgcatcaggcgccccgcacgctgccgggggccgcctc Rv3842c 89 atgacatgggccgacgaggtgctcgccggacatccctttgtggttgctca ccgtggtgcgtcggcggctcggccggagcatacccttgccgcctacgacc tggcgctcaaagagggcgccgacggcgtggaatgtgatgtgcggttgacc cgggacgggcatctggtctgtgtgcatgaccgccgcctggaccgaacctc gacgggagccggcttggtcagcacgatgacgctggcccagctacgcgagc tggagtacggcgcgtggcacgacagctggcgccccgacggttcgcacggc gacaccagtctgctgaccctggacgcgcttgtttcgctggttttggactg gcaccggccggtgaagatcttcgtcgagaccaagcatcccgtccgatacg gctcgctggtggaaaacaagctgctggcgctgctacaccggttcggtatt gccgcacccgcctccgcagatcgatcccgtgcggtggtgatgtcgttttc ggccgccgcggtctggcggatccggcgggctgcaccgctgctgccgacgg tgttgctcggcaagaccccccgatacctgaccagcagtgcggccacggcg gtcggggcaaccgccgtgggaccctcactgcctgcgttaaaggaatatcc gcaactcgttgaccgctcggcagctcagggccgggcggtgtactgctgga acgtcgatgagtacgaggacatcgacttttgccgggaggtcggggtggcc tggattggtactcaccaccccggccgcaccaaggcctggctggaagacgg gcgggcgaacgggaccactcgc Rv3908 90 gtgtccgacggcgaacaagccaaatcacgtcgacgccgggggcggcgccg cgggcggcgcgctgcggctacagccgagaatcacatggacgcccaaccgg ccggcgacgccaccccgaccccggcaacggcgaagcggtcccggtcccgc tcacctcgtcgcgggtcgactcggatgcgcaccgtgcacgaaacatcggc tggagggttggtcattgacggtatcgacggtccacgagacgcgcaggtcg cggctctgatcggccgcgtcgaccggcgcggccggctgctgtggtcgcta cccaaggggcacatcgagttgggcgagaccgccgagcagaccgccatccg cgaggtcgccgaggagaccggcatccgcggcagtgtgctcgccgcgctgg ggcgcatcgactactggttcgtcaccgacggccggcgggtgcacaagacc gtccaccattatttgatgcggtttttaggcggagagctgtccgacgaaga cctcgaggtagccgaggtagcctgggtgccgatccgggaactgccgtctc gactggcctacgccgacgaacgtcgactagccgaggtggccgacgaactg atcgacaagctgcagagcgacggccccgccgcgcttccgccgctaccacc cagctcgcctcgtcgacggccgcaaacgcattcacgcgctcgtcatgccg atgactcagcaccgggtcagcacaacggtcccgggccggggccg

Preferably the immunogenic portions are selected from the group consisting of the sequences presented in Table 1 and the nucleic acid sequences are selected from the sequences presented in Table 2.

In another embodiment, the vaccine is a multiphase vaccine, where the polypeptides or fragments hereof are fused to other antigens with efficacy as prophylactic vaccines, where the fusion partner is selected from e.g. the group consisting of ESAT-6, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64, MPT64, Ag85A, Ag85B (MPT59), MPB59, Ag85C, 19 kDa lipoprotein, MPT32.

The invention further discloses a therapeutic vaccine against tuberculosis comprising one or more polypeptides or fragments hereof, which polypeptides are expressed during the latent stage of the mycobacteria infection, which stage is characterized by low-oxygen tension in the microenvironment of the mycobacteria, or nucleic acids encoding these polypeptides.

Preferably, the therapeutic and multiphase vaccine comprises an additional delivery system selected from among, live recombinant vaccines, that is gene-modified organisms such as bacteria or viruses expressing mycobacteria genes, or immunogenic delivery systems such as, DNA vaccines, that is plasmids expressing genes or gene fragments for the proteins described above, or protein vaccines, that is the proteins themselves or synthetic peptides derived from the proteins themselves delivered in a delivery system such as an adjuvant.

The invention further discloses a therapeutic vaccine in which the amino acid sequence is lipidated so as to allow a self-adjuvanting effect of the polypeptide.

The invention also discloses a method for treating an animal, including a human being, with tuberculosis caused by virulent mycobacteria, e.g., by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis, comprising administering to the animal the above-mentioned vaccine.

The invention also discloses a method for immunizing an animal, including a human being, against tuberculosis caused by virulent mycobacteria, e.g., by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis, comprising administering to the animal the above mentioned vaccine.

In a still further embodiment, the invention discloses an immunogenic composition comprising a polypeptide as defined above, preferably in the form of a vaccine or in the form of a diagnostic reagent. The diagnostic reagent can be in the form of a skin test reagent (administered by the transcutaneous, subcutaneous or intradermal routes), a serological reagent or a reagent for stimulating a cell-mediated reaction.

In another embodiment, the invention discloses a nucleic acid fragment in isolated form which

-   -   (a) comprises a nucleic acid sequence which encodes a         polypeptide as defined above, or comprises a nucleic acid         sequence complementary thereto; or     -   (b) has a length of at least 10 nucleotides and hybridizes         readily under stringent hybridization conditions with a         nucleotide sequence selected from the nucleotide sequences         presented in Table 2 or a sequence complementary thereto, or         with a nucleotide sequence selected from a sequence in (a)

The nucleic acid fragment is preferably a DNA fragment. The fragment can be used as a pharmaceutical.

In another embodiment, the invention discloses a vaccine comprising a nucleic acid fragment according to the invention, optionally inserted in a vector, the vaccine effecting in vivo expression of antigen by a human being or other mammal or animal, to whom the vaccine has been administered, the amount of expressed antigen being effective to confer substantially increased resistance to tuberculosis caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis, in an animal, including a human being.

In a further embodiment, the invention discloses the use of a nucleic acid fragment according to the invention for the preparation of a composition for the diagnosis of tuberculosis caused by virulent mycobacteria, e. g., by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis, and the use of a nucleic acid fragment according to the invention for the preparation of a pharmaceutical composition for the vaccination against tuberculosis caused by virulent mycobacteria, e.g., by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis.

In a still further embodiment, the invention discloses a vaccine for immunizing an human being or other mammal or animal, against tuberculosis caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis, comprising as the effective component a non-pathogenic microorganism, wherein at least one copy of a DNA fragment comprising a DNA sequence encoding a polypeptide as defined above has been incorporated into the microorganism (e.g., placed on a plasmid or in the genome) in a manner allowing the microorganism to express and optionally secrete the polypeptide.

In another embodiment, the invention discloses a replicable expression vector, which comprises a nucleic acid fragment according to the invention, and a transformed cell harboring at least one such vector.

In another embodiment, the invention discloses a method for producing a polypeptide as defined above, comprising

-   -   (a) inserting a nucleic acid fragment according to the invention         into a vector that is able to replicate in a host cell,         introducing the resulting recombinant vector into the host cell,         culturing the host cell in a culture medium under conditions         sufficient to effect expression of the polypeptide, and         recovering the polypeptide from the host cell or culture medium;     -   (b) isolating the polypeptide from a whole mycobacterium, e.g.         Mycobacterium tuberculosis, Mycobacterium africanum or         Mycobacterium bovis, from culture filtrate or from lysates or         fractions thereof; or     -   (c) synthesizing the polypeptide e.g. by solid or liquid phase         peptide synthesis.

The invention also discloses a method of diagnosing tuberculosis caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis, in an animal, including a human being, comprising intradermally injecting, in the animal, a polypeptide as defined above or an immunogenic composition as defined above, a positive skin response at the location of injection being indicative of the animal having tuberculosis, and a negative skin response at the location of injection being indicative of the animal not having tuberculosis.

In another embodiment, the invention discloses a method for immunizing an animal, including a human being, against tuberculosis caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis, comprising administering to the animal the polypeptide as defined above, the immunogenic composition according to the invention, or the vaccine according to the invention.

Another embodiment of the invention discloses a monoclonal or polyclonal antibody, which is specifically reacting with a polypeptide as defined above in an immuno assay, or a specific binding fragment of said antibody. Preferably, said antibody is for use as a diagnostic reagent, e.g. for detection of mycobacteria antigens in sputum, urine or other body fluids of an infected animal, including a human being.

In a further embodiment the invention discloses a pharmaceutical composition that comprises an immunologically responsive amount of at least one member selected from the group consisting of:

-   -   (a) a polypeptide selected from the sequences presented in Table         1, or an immunogenic portion thereof;     -   (b) an amino acid sequence which has a sequence identity of at         least 70% to any one of said polypeptides in (a) and is         immunogenic;     -   (c) a fusion polypeptide comprising at least one polypeptide or         amino acid sequence according to (a) or (b) and at least one         fusion partner;     -   (d) a nucleic acid sequence which encodes a polypeptide or amino         acid sequence according to (a), (b) or (c);     -   (e) a nucleic acid sequence which is complementary to a sequence         according to (d);     -   (f) a nucleic acid sequence which has a length of at least 10         nucleotides and which hybridizes under stringent conditions with         a nucleic acid sequence according to (d) or (e); and     -   (g) a non-pathogenic micro-organism which has incorporated (e.g.         placed on a plasmid or in the genome) therein a nucleic acid         sequence according to (d), (e) or (f) in a manner to permit         expression of a polypeptide encoded thereby.

In a still further embodiment the invention discloses a method for stimulating an immunogenic response in an animal which comprises administering to said animal an immunologically stimulating amount of at least one member selected from the group consisting of:

-   -   (a) a polypeptide selected from the sequences presented in Table         1, or an immunogenic portion thereof;     -   (b) an amino acid sequence which has a sequence identity of at         least 70% to any one of said polypeptides in (a) and is         immunogenic;     -   (c) a fusion polypeptide comprising at least one polypeptide or         amino acid sequence according to (a) or (b) and at least one         fusion partner;     -   (d) a nucleic acid sequence which encodes a polypeptide or amino         acid sequence according to (a), (b) or (c);     -   (e) a nucleic acid sequence that is complementary to a sequence         according to (d);     -   (f) a nucleic acid sequence which has a length of at least 10         nucleotides and which hybridizes under stringent conditions with         a nucleic acid sequence according to (d) or (e); and     -   (g) a non-pathogenic micro-organism which has incorporated         therein (e.g. placed on a plasmid or in the genome) a nucleic         acid sequence according to (d), (e) or (f) in a manner to permit         expression of a polypeptide encoded thereby.

The vaccine, immunogenic composition and pharmaceutical composition according to the invention can be used therapeutically in a subject infected with a virulent mycobacterium combined with a prophylactic composition in a subject to prevent further infection with a virulent mycobacterium.

The invention also discloses a method for diagnosing previous or ongoing infection with a virulent mycobacterium, said method comprising

-   -   (a) contacting a sample, e.g. a blood sample, with a composition         comprising an antibody according to the invention, a nucleic         acid fragment according to the invention and/or a polypeptide as         defined above, or     -   (b) contacting a sample, e.g. a blood sample comprising         mononuclear cells (e.g. T-lymphocytes), with a composition         comprising one or more polypeptides as defined above in order to         detect a positive reaction, e.g. proliferation of the cells or         release of cytokines such as IFN-γ.

Finally, the invention, discloses a method of diagnosing Mycobacterium tuberculosis infection in a subject comprising:

-   -   (a) contacting a polypeptide as defined above with a bodily         fluid of the subject;     -   (b) detecting binding of a antibody to said polypeptide, said         binding being an indication that said subject is infected by         Mycobacterium tuberculosis or is susceptible to Mycobacterium         tuberculosis infection.

Definitions

Polypeptides

The word “polypeptide” in the present invention should have its usual meaning. That is an amino acid chain of any length, including a full-length protein, oligopeptides, short peptides and fragments thereof, wherein the amino acid residues are linked by covalent peptide bonds.

The polypeptide may be chemically modified by being glycosylated, by being lipidated (e.g. by chemical lipidation with palmitoyloxy succinimide as described by Mowat et al. 1991 or with dodecanoyl chloride as described by Lustig et al. 1976), by comprising prosthetic groups, or by containing additional amino acids such as e.g. a his-tag or a signal peptide.

Each polypeptide may thus be characterized by specific amino acids and be encoded by specific nucleic acid sequences. It will be understood that such sequences include analogues and variants produced by recombinant or synthetic methods wherein such polypeptide sequences have been modified by substitution, insertion, addition or deletion of one or more amino acid residues in the recombinant polypeptide and still be immunogenic in any of the biological assays described herein. Substitutions are preferably “conservative”. These are defined according to the following table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other. The amino acids in the third column are indicated in one-letter code.

ALIPHATIC Non-polar GAP ILV Polar-uncharged CSTM NQ Polar-charged DE KR AROMATIC HFWY

A preferred polypeptide within the present invention is an immunogenic antigen from M. tuberculosis produced when the organism is subjected to the stresses associated with latent infection. Such antigen can for example also be derived from the M. tuberculosis cell and/or M. tuberculosis culture filtrate. Thus, a polypeptide comprising an immunogenic portion of one of the above antigens may consist entirely of the immunogenic portion, or may contain additional sequences. The additional sequences may be derived from the native M. tuberculosis antigen or be heterologous and such sequences may, but need not, be immunogenic.

Each polypeptide is encoded by a specific nucleic acid sequence. It will be understood that such sequences include analogues and variants hereof wherein such nucleic acid sequences have been modified by substitution, insertion, addition or deletion of one or more nucleic acids. Substitutions are preferably silent substitutions in the codon usage that will not lead to any change in the amino acid sequence, but may be introduced to enhance the expression of the protein.

In the present context the term “substantially pure polypeptide fragment” means a polypeptide preparation which contains at most 5% by weight of other polypeptide material with which it is natively associated (lower percentages of other polypeptide material are preferred, e.g. at most 4%, at most 3%, at most 2%, at most 1%, and at most ½%). It is preferred that the substantially pure polypeptide is at least 96% pure, i.e. that the polypeptide constitutes at least 96% by weight of total polypeptide material present in the preparation, and higher percentages are preferred, such as at least 97%, at least 98%, at least 99%, at least 99.25%, at least 99.5%, and at least 99.75%. It is especially preferred that the polypeptide fragment is in “essentially pure form”, i.e. that the polypeptide fragment is essentially free of any other antigen with which it is natively associated, i.e. free of any other antigen from bacteria belonging to the tuberculosis complex or a virulent mycobacterium. This can be accomplished by preparing the polypeptide fragment by means of recombinant methods in a non-mycobacterial host cell as will be described in detail below, or by synthesizing the polypeptide fragment by the well-known methods of solid or liquid phase peptide synthesis, e.g. by the method described by Merrifield or variations thereof.

By the term “virulent mycobacterium” is understood a bacterium capable of causing the tuberculosis disease in an animal or in a human being. Examples of virulent mycobacteria include but are not limited to M. tuberculosis, M. africanum, and M. bovis. Examples of relevant animals are cattle, possums, badgers and kangaroos.

By “a TB patient” is understood an individual with culture or microscopically proven infection with virulent mycobacteria, and/or an individual clinically diagnosed with TB and who is responsive to anti-TB chemotherapy. Culture, microscopy and clinical diagnosis of TB are well known by any person skilled in the art.

By the term “PPD-positive individual” is understood an individual with a positive Mantoux test or an individual where PPD induces a positive in vitro recall response determined by release of IFN-γ.

By “a latently infected individual” is understood an individual, who has been infected by a virulent mycobacterium, e.g. M. tuberculosis, but shows no sign of active tuberculosis. It is likely that individuals who have been vaccinated, e.g. by BCG, or treated for TB may still retain the mycobacteria within their bodies, although this is currently impossible to prove since such individuals would be expected to be positive if tested for PPD reactivity. Nonetheless, in its most accurate sense, “latently-infected” may be used to describe any individual who has M. tuberculosis residing in their tissues but who is not clinically ill.

By the term “delayed type hypersensitivity reaction” (DTH) is understood a T-cell mediated inflammatory response elicited after the injection of a polypeptide into, or application to, the skin, said inflammatory response appearing 72-96 hours after the polypeptide injection or application.

By the term “IFN-γ” is understood interferon-gamma. The measurement of IFN-γ is used as an indication of an immunological response.

By the terms “nucleic acid fragment” and “nucleic acid sequence” are understood any nucleic acid molecule including DNA, RNA , LNA (locked nucleic acids), PNA, RNA, dsRNA and RNA-DNA-hybrids. Also included are nucleic acid molecules comprising non-naturally occurring nucleosides. The term includes nucleic acid molecules of any length e.g. from 10 to 10000 nucleotides, depending on the use. When the nucleic acid molecule is for use as a pharmaceutical, e.g. in DNA therapy, or for use in a method for producing a polypeptide according to the invention, a molecule encoding at least one epitope is preferably used, having a length from about 18 to about 1000 nucleotides, the molecule being optionally inserted into a vector. When the nucleic acid molecule is used as a probe, as a primer or in antisense therapy, a molecule having a length of 10-100 is preferably used. According to the invention, other molecule lengths can be used, for instance a molecule having at least 12, 15, 21, 24, 27, 30, 33, 36, 39, 42, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500 or 1000 nucleotides (or nucleotide derivatives), or a molecule having at most 10000, 5000, 4000, 3000, 2000, 1000, 700, 500, 400, 300, 200, 100, 50, 40, 30 or 20 nucleotides (or nucleotide derivatives).

The term “stringent” when used in conjunction with hybridization conditions is as defined in the art, i.e. the hybridization is performed at a temperature not more than 15-20° C. under the melting point T_(m), cf. Sambrook et al, 1989, pages 11.45-11.49. Preferably, the conditions are “highly stringent”, i.e. 5-10° C. under the melting point T_(m).

Throughout this specification, unless the context requires otherwise, the word “comprise”, or variations thereof such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

Sequence Identity

The term “sequence identity” indicates a quantitative measure of the degree of homology between two amino acid sequences of equal length or between two nucleotide sequences of equal length. The two sequences to be compared must be aligned to best possible fit allowing the insertion of gaps or alternatively, truncation at the ends of the protein sequences. The sequence identity can be calculated as

$\frac{\left( {N_{ref} - N_{dif}} \right)100}{N_{ref}},$

wherein N_(dif) is me total number of non-identical residues in the two sequences when aligned and wherein N_(ref) is the number of residues in one of the sequences. Hence, the DNA sequence AGTCAGTC [SEQ ID NO: 184] will have a sequence identity of 75% with the sequence AATCAATC, SEQ ID NO: 185 (N_(dif)=2 and N_(ref)=8). A gap is counted as non-identity of the specific residue(s), i.e. the DNA sequence AGTGTC [SEQ ID NO: 186] will have a sequence identity of 75% with the DNA sequence AGTCAGTC, SEQ ID NO: 187, (N_(dif)=2 and N_(ref)=8). Sequence identity can alternatively be calculated by the BLAST program e.g. the BLASTP program (Pearson, 1988, or online through the NIH website). In one aspect of the invention, alignment is performed with the sequence alignment method ClustalW with default parameters as described by Thompson J., et al. 1994 and as available through online sources.

A preferred minimum percentage of sequence identity is at least 80%, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, and at least 99.5%.

Immunogenic Portion

In a preferred embodiment of the invention, the polypeptide comprises an immunogenic portion of the polypeptide, such as an epitope for a B-cell or T-cell.

The immunogenic portion of a polypeptide is a part of the polypeptide, which elicits an immune response in an animal or a human being, and/or in a biological sample determined by any of the biological assays described herein. The immunogenic portion of a polypeptide may be a T-cell epitope or a B-cell epitope. Immunogenic portions can be related to one or a few relatively small parts of the polypeptide, they can be scattered throughout the polypeptide sequence or be situated in specific parts of the polypeptide. For a few polypeptides, epitopes have even been demonstrated to be scattered throughout the polypeptide covering the full sequence (Ravn et al 1999). In order to identify relevant T-cell epitopes which are recognized during an immune response, it is possible to use overlapping oligopeptides for the detection of MHC class II epitopes, preferably synthetic, having a length of e.g. 20 amino acid residues derived from the polypeptide. These peptides can be tested in biological assays (e.g. the IFN-γ assay as described herein) and some of these will give a positive response (and thereby be immunogenic) as evidence for the presence of a T cell epitope in the peptide. For the detection of MHC class I epitopes it is possible to predict peptides that will bind (Stryhn et al. 1996) and hereafter produce these peptides synthetic and test them in relevant biological assays, e.g. the IFNγ assay as described herein. The peptides preferably having a length of, e.g., 8 to 11 amino acid residues derived from the polypeptide. B-cell epitopes can be determined by analyzing the B cell recognition to overlapping peptides covering the polypeptide of interest as, e.g., described in Harboe et al 1998.

Although the minimum length of a T-cell epitope has been shown to be at least 6 amino acids; it is normal that such epitopes are constituted of longer stretches of amino acids. Hence, it is preferred that the polypeptide fragment of the invention has a length of at least 7 amino acid residues, such as at least 8, at least 9, at least 10, at least 12, at least 14, at least 16, at least 18, at least 20, at least 22, at least 24, and at least 30 amino acid residues. Hence, in important embodiments of the inventive method, it is preferred that the polypeptide fragment has a length of at most 50 amino acid residues, such as at most 40, 35, 30, 25, and 20 amino acid residues. It is expected that the peptides having a length of from 10 to 20 amino acid residues will prove to be most efficient as MHC class II epitopes and therefore especially preferred lengths of the polypeptide fragment used in the inventive method are 18, such as 15, 14, 13, 12 and even 11 amino acid residues. It is expected that the peptides having a length of from 7 to 12 amino acid residues will prove to be most efficient as MHC class I epitopes and therefore especially preferred lengths of the polypeptide fragment used in the inventive method are 11, such as 10, 9, 8 and even 7 amino acid residues.

Immunogenic portions of polypeptides may be recognized by a broad part (high frequency) or by a minor part (low frequency) of the genetically heterogeneous human population. In addition some immunogenic portions induce high immunological responses (dominant), whereas others induce lower, but still significant, responses (subdominant). High frequency or low frequency can be related to the immunogenic portion binding to widely distributed MHC molecules (HLA type) or even by multiple MHC molecules (Sinigaglia, 1988, Kilgus, 1991).

In the context of providing candidate molecules for a new vaccine against tuberculosis, the subdominant epitopes are however as relevant as are the dominant epitopes since it has been shown (Olsen, 2000) that such epitopes can induce protection regardless of the fact that they are not as strongly or broadly recognized.

Variants

A common feature of the polypeptides of the invention is their capability to induce an immunological response as illustrated in the examples. It is understood that a variant of a polypeptide of the invention produced by substitution, insertion, addition or deletion may also be immunogenic as determined by any of the assays described herein.

Immune Individual

An immune individual is defined as a person or an animal, which has cleared or controlled an infection with virulent mycobacteria or has received a vaccination with M. bovis BCG.

Immune Response

The immune response may be monitored by one of the following methods:

-   -   An in vitro cellular response is determined by induction of the         release of a relevant cytokine such as IFN-γ from, or the         induction of proliferation in lymphocytes withdrawn from an         animal or human being currently or previously infected with         virulent mycobacteria or immunized with the relevant         polypeptide. The induction being performed by the addition of         the polypeptide or the immunogenic portion of the polypeptide to         a suspension comprising from 2×10⁵ cells to 4×10⁵ cells per         well. The cells being isolated from either the blood, the         spleen, the liver or the lung and the addition of the         polypeptide or the immunogenic portion resulting in a         concentration of not more than 20 μg per ml suspension and the         stimulation being performed from two to five days. For         monitoring cell proliferation the cells are pulsed with         radioactive labeled Thymidine and after 16-22 hours of         incubation detecting the proliferation by liquid scintillation         counting. A positive response is defined as being a response         more than background plus two standard deviations. The release         of IFN-γ can be determined by the ELISA method, which is well         known to a person skilled in the art. A positive response being         a response more than background plus two standard deviations.         Other cytokines than IFN-γ could be relevant when monitoring the         immunological response to the polypeptide, such as IL-12, TNF-α,         IL-4, IL-5, IL-10, IL-6, TGF-β. Another and more sensitive         method for detecting the immune response is the ELISpot method,         in which the frequency of IFN-γ producing cells is determined.         In an ELIspot plate (MAHA, Millipore) precoated with anti-murine         IFN-γ antibodies (PharMingen) graded numbers of cells isolated         from either blood, spleen, or lung (typically between 1 to 4×10⁵         cells/well) are incubated for 24-32 hrs in the presence of the         polypeptide or the immunogenic portion resulting in a         concentration of not more than 20 μg per ml. The plates are         subsequently incubated with biotinylated anti-IFN-γ antibodies         followed by a streptavidin-alkaline phosphatase incubation. The         IFN-γ producing cells are identified by adding BCIP/NBT (Sigma),         the relevant substrate giving rise to spots. These spots can be         enumerated using a dissection microscope. It is also a         possibility to determine the presence of mRNA coding for the         relevant cytokine by the use of the PCR technique. Usually one         or more cytokines will be measured utilizing for example PCR,         ELISPOT or ELISA. It will be appreciated by a person skilled in         the art that a significant increase or decrease in the amount of         any of these cytokines induced by a specific polypeptide can be         used in evaluation of the immunological activity of the         polypeptide.     -   An in vitro cellular response may also be determined by the use         of T cell lines derived from an immune individual or an M.         tuberculosis-infected person where the T cell lines have been         driven with either live mycobacteria, extracts from the         bacterial cell or culture filtrate for 10 to 20 days with the         addition of IL-2. The induction being performed by addition of         not more than 20 μg polypeptide per ml suspension to the T cell         lines containing from 1×10⁵ cells to 3×10⁵ cells per well and         incubation being performed from two to six days. The induction         of IFN-γ or release of another relevant cytokine is detected by         ELISA. The stimulation of T cells can also be monitored by         detecting cell proliferation using radioactively labeled         Thymidine as described above. For both assays a positive         response being a response more than background plus two standard         deviations.     -   An in vivo cellular response may be determined as a positive DTH         response after intradermal injection or local application patch         of at most 100 μg of the polypeptide or the immunogenic portion         to an individual who is clinically or subclinically infected         with a virulent mycobacterium, a positive response having a         diameter of at least 5 mm 72-96 hours after the injection or         application.     -   An in vitro humoral response is determined by a specific         antibody response in an immune or infected individual. The         presence of antibodies may be determined by an ELISA technique         or a Western blot where the polypeptide or the immunogenic         portion is absorbed to either a nitrocellulose membrane or a         polystyrene surface. The serum is preferably diluted in PBS from         1:10 to 1:100 and added to the absorbed polypeptide and the         incubation being performed from 1 to 12 hours. By the use of         labeled secondary antibodies the presence of specific antibodies         can be determined by measuring the OD e.g. by ELISA where a         positive response is a response of more than background plus two         standard deviations or alternatively a visual response in a         Western blot.     -   Another relevant parameter is measurement of the protection in         animal models induced after vaccination with the polypeptide in         an adjuvant or after DNA vaccination. Suitable animal models         include primates, guinea pigs or mice, which are challenged with         an infection of a virulent Mycobacterium. Readout for induced         protection could be decrease of the bacterial load in target         organs compared to non-vaccinated animals, prolonged survival         times compared to non-vaccinated animals and diminished weight         loss compared to non-vaccinated animals.

Preparation Methods

In general, M. tuberculosis antigens, and DNA sequences encoding such antigens, may be prepared using any one of a variety of procedures.

They may be purified as native proteins from the M. tuberculosis cell or culture filtrate by procedures such as those described above. Immunogenic antigens may also be produced recombinantly using a DNA sequence encoding the antigen, which has been inserted into an expression vector and expressed in an appropriate host. Examples of host cells are E. coli. The polypeptides or immunogenic portion hereof can also be produced synthetically having fewer than about 100 amino acids, and generally fewer than 50 amino acids and may be generated using techniques well known to those ordinarily skilled in the art, such as commercially available solid-phase techniques where amino acids are sequentially added to a growing amino acid chain.

In the construction and preparation of plasmid DNA encoding the polypeptide as defined for DNA vaccination a host strain such as E. coli can be used. Plasmid DNA can then be prepared from cultures of the host strain carrying the plasmid of interest, and purified using e.g. the Qiagen Giga-Plasmid column kit (Qiagen, Santa Clarita, Calif., USA) including an endotoxin removal step. It is preferred that plasmid DNA used for DNA vaccination is endotoxin free.

Fusion Proteins

The immunogenic polypeptides may also be produced as fusion proteins, by which methods superior characteristics of the polypeptide of the invention can be achieved. For instance, fusion partners that facilitate export of the polypeptide when produced recombinantly, fusion partners that facilitate purification of the polypeptide, and fusion partners which enhance the immunogenicity of the polypeptide fragment of the invention are all interesting possibilities. Therefore, the invention also pertains to a fusion polypeptide comprising at least one polypeptide or immunogenic portion defined above and at least one fusion partner. The fusion partner can, in order to enhance immunogenicity, be another polypeptide derived from M. tuberculosis, such as of a polypeptide fragment derived from a bacterium belonging to the tuberculosis complex, such as ESAT-6, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64, MPT64, Ag85A, Ag85B (MPT59), MPB59, Ag85C, 19 kDa lipoprotein, MPT32 and alpha-crystalline, or at least one T-cell epitope of any of the above mentioned antigens (Skjøt et al 2000; Danish Patent application PA 2000 00666; Danish Patent application PA 1999 01020; U.S. patent application Ser. No. 09/505,739; Rosenkrands et al 1998; Nagai et al 1991). The invention also pertains to a fusion polypeptide comprising mutual fusions of two or more of the polypeptides (or immunogenic portions thereof) of the invention.

Other fusion partners, which could enhance the immunogenicity of the product, are lymphokines such as IFN-γ, IL-2 and IL-12. In order to facilitate expression and/or purification, the fusion partner can e.g. be a bacterial fimbrial protein, e.g. the pilus components pilin and papA; protein A; the ZZ-peptide (ZZ-fusions are marketed by Pharmacia in Sweden); the maltose binding protein; glutathione S-transferase; β-galactosidase; or poly-histidine. Fusion proteins can be produced recombinantly in a host cell, which could be E. coli, and it is a possibility to induce a linker region between the different fusion partners.

Other interesting fusion partners are polypeptides, which are lipidated so that the immunogenic polypeptide is presented in a suitable manner to the immune system. This effect is e.g. known from vaccines based on the Borrelia burgdorferi OspA polypeptide as described in e.g. WO 96/40718 A or vaccines based on the Pseudomonas aeruginosa OprI lipoprotein (Cote-Sierra J 1998). Another possibility is N-terminal fusion of a known signal sequence and an N-terminal cystein to the immunogenic polypeptide. Such a fusion results in lipidation of the immunogenic polypeptide at the N-terminal cystein, when produced in a suitable production host.

Uses

Protein Vaccine

Another part of the invention pertains to a vaccine composition comprising a polypeptide (or at least one immunogenic portion thereof) or fusion polypeptide according to the invention. In order to ensure optimum performance of such a vaccine composition it is preferred that it comprises an immunologically and pharmaceutically acceptable carrier, vehicle or adjuvant.

An effective vaccine, wherein a polypeptide of the invention is recognized by the animal, will in an animal model be able to decrease bacterial load in target organs, prolong survival times and/or diminish weight loss after challenge with a virulent Mycobacterium, compared to non-vaccinated animals

Suitable carriers are selected from the group consisting of a polymer to which the polypeptide(s) is/are bound by hydrophobic non-covalent interaction, such as a plastic, e.g. polystyrene, or a polymer to which the polypeptide(s) is/are covalently bound, such as a polysaccharide, or a polypeptide, e.g. bovine serum albumin, ovalbumin or keyhole limpet haemocyanin. Suitable vehicles are selected from the group consisting of a diluent and a suspending agent. The adjuvant is preferably selected from the group consisting of dimethyldioctadecylammonium bromide (DDA), Quil A, poly I:C, aluminum hydroxide, Freund's incomplete adjuvant, IFN-γ, IL-2, IL-12, monophosphoryl lipid A (MPL), Trehalose Dimycolate (TDM), Trehalose Dibehenate and muramyl dipeptide (MDP).

Preparation of vaccines which contain peptide sequences as active ingredients is generally well understood in the art, as exemplified by U.S. Pat. Nos. 4,608,251; 4,601,903; 4,599,231 and 4,599,230, all incorporated herein by reference.

Other methods of achieving adjuvant effect for the vaccine include use of agents such as aluminum hydroxide or phosphate (alum), synthetic polymers of sugars (Carbopol), aggregation of the protein in the vaccine by heat treatment, aggregation by reactivating with pepsin treated (Fab) antibodies to albumin, mixture with bacterial cells such as C. parvum or endotoxins or lipopolysaccharide components of gram-negative bacteria, emulsion in physiologically acceptable oil vehicles such as mannide mono-oleate (Aracel A) or emulsion with 20 percent solution of a perfluorocarbon (Fluosol-DA) used as a block substitute may also be employed. Other possibilities involve the use of immune modulating substances such as cytokines or synthetic IFN-γ inducers such as poly I:C in combination with the above-mentioned adjuvants.

Another interesting possibility for achieving adjuvant effect is to employ the technique described in Gosselin et al., 1992 (which is hereby incorporated by reference herein). In brief, a relevant antigen such as an, antigen of the present invention can be conjugated to an antibody (or antigen binding antibody fragment) against the Fcγ receptors on monocytes/macrophages.

The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective and immunogenic. The quantity to be administered depends on the subject to be treated, including, e.g., the capacity of the individual's immune system to mount an immune response, and the degree of protection desired. Suitable dosage ranges are of the order of several hundred micrograms active ingredient per vaccination with a preferred range from about 0.1 μg to 1000 μg, such as in the range from about 1 μg to 300 μg, and especially in the range from about 10 μg to 50 μg. Suitable regimens for initial administration and booster shots are also variable but are typified by an initial administration followed by subsequent inoculations or other administrations.

The manner of application may be varied widely. Any of the conventional methods for administration of a vaccine are applicable. These are believed to include oral application on a solid physiologically acceptable base or in a physiologically acceptable dispersion, parenterally, by injection or the like. The dosage of the vaccine will depend on the route of administration and will vary according to the age of the person to be vaccinated and, to a lesser degree, the size of the person to be vaccinated.

The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations. For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1-2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and advantageously contain 10-95% of active ingredient, preferably 25-70%.

In many instances, it will be necessary to have multiple administrations of the vaccine. Especially, vaccines can be administered to prevent an infection with virulent mycobacteria, a prophylactic vaccine, and/or to treat established mycobacterial infection, a therapeutic vaccine. When administered to prevent an infection, the vaccine is given prophylactically, before definitive clinical signs, diagnosis or identification of an infection TB are present. Since the current vaccine BCG appears to induce an effective, but short-lived immune response, prophylactic vaccines may also be designed to be used as booster vaccines. Such booster vaccines are given to individuals who have previously received a vaccination, with the intention of prolonging the period of protection. In instances where the individual has already become infected or is suspected to have become infected, the previous vaccination may have provided sufficient immunity to prevent primary disease, but as discussed previously, boosting this immune response will not help against the latent infection. In such a situation, the vaccine will necessarily have to be a therapeutic vaccine designed for efficacy against the latent stage of infection. A combination of a prophylactic vaccine and a therapeutic vaccine, which is active against both primary and latent infection, constitutes a multiphase vaccine.

Due to genetic variation, different individuals may react with immune responses of varying strength to the same polypeptide. Therefore, the vaccine according to the invention may comprise several different polypeptides in order to increase the immune response. The vaccine may comprise two or more polypeptides or immunogenic portions, where all of the polypeptides are as defined above, or some but not all of the peptides may be derived from virulent mycobacteria. In the latter example, the polypeptides not necessarily fulfilling the criteria set forth above for polypeptides may either act due to their own immunogenicity or merely act as adjuvants.

The vaccine may comprise 1-20, such as 2-20 or even 3-20 different polypeptides or fusion polypeptides, such as 3-10 different polypeptides or fusion polypeptides.

The invention also pertains to a method for immunizing an animal, including a human being, against TB caused by virulent mycobacteria, comprising administering to the animal the polypeptide of the invention, or a vaccine composition of the invention as described above, or a living vaccine described above.

The invention also pertains to a method for producing an immunologic composition according to the invention, the method comprising preparing, synthesizing or isolating a polypeptide according to the invention, and solubilizing or dispersing the polypeptide in a medium for a vaccine, and optionally adding other M. tuberculosis antigens and/or a carrier, vehicle and/or adjuvant substance.

DNA Vaccine.

The nucleic acid fragments of the invention may be used for effecting in vivo expression of antigens, i.e. the nucleic acid fragments may be used in so-called DNA vaccines as reviewed in Ulmer et al 1993, which is included by reference.

Hence, the invention also relates to a vaccine comprising a nucleic acid fragment according to the invention, the vaccine effecting in vivo expression of antigen by an animal, including a human being, to whom the vaccine has been administered, the amount of expressed antigen being effective to confer substantially increased resistance to infections caused by virulent mycobacteria in an animal, including a human being.

The above mentioned definitions and distinctions of prophylactic-, booster-, therapeutic- and multiphase vaccines also applies for DNA vaccines

The efficacy of such a DNA vaccine can possibly be enhanced by administering the gene encoding the expression product together with a DNA fragment encoding a polypeptide that has the capability of modulating an immune response.

Live Recombinant Vaccines

One possibility for effectively activating a cellular immune response for a vaccine can be achieved by expressing the relevant antigen in a vaccine in a non-pathogenic microorganism or virus. Well-known examples of such microorganisms are Mycobacterium bovis BCG, Salmonella and Pseudomona and examples of viruses are Vaccinia Virus and Adenovirus.

Therefore, another important aspect of the present invention is an improvement of the living BCG vaccine presently available, wherein one or more copies of a DNA sequence encoding one or more polypeptide as defined above has been incorporated into the genome of the micro-organism in a manner allowing the micro-organism to express and secrete the polypeptide. The incorporation of more than one copy of a nucleotide sequence of the invention is contemplated to enhance the immune response.

Another possibility is to integrate the DNA encoding the polypeptide according to the invention in an attenuated virus such as the vaccinia virus or Adenovirus (Rolph et al 1997). The recombinant vaccinia virus is able to replicate within the cytoplasma of the infected host cell and the polypeptide of interest can therefore induce an immune response, which is envisioned to induce protection against TB.

Therapeutic Vaccine.

The invention also relates to the use of a polypeptide or nucleic acid of the invention for use as therapeutic vaccines as have been described by D. Lowrie (Lowrie, 1999) using DNA vaccine encoding HSP65 from M. leprae. Antigens with therapeutic properties may be identified based on their ability to diminish the severity of M. tuberculosis infection in experimental animals or prevent reactivation of previous infection, when administered as a vaccine. The composition used for therapeutic vaccines can be prepared as described above for vaccines.

Diagnostic Protein

The invention also relates to a method of diagnosing latent TB caused by a virulent mycobacterium in an animal, including a human being, comprising intradermally injecting, in the animal, a polypeptide according to the invention, a positive skin response at the location of injection being indicative of the animal having TB, and a negative skin response at the location of injection being indicative of the animal not having TB.

When diagnosis of latent infection with virulent mycobacteria is the aim, a blood sample comprising mononuclear cells (i.e. T-Iymphocytes) from a patient is contacted with a sample of one or more polypeptides of the invention. This contacting can be performed in vitro and a positive reaction could e.g. be proliferation of the T-cells or release of cytokines such as IFN-γ into the extracellular phase. It is also conceivable to contact a serum sample from a subject with a polypeptide of the invention, the demonstration of a binding between antibodies in the serum sample and the polypeptide being indicative of previous or ongoing infection.

The invention therefore also relates to an in vitro method for diagnosing latent infection in an animal or a human being with a virulent mycobacterium, the method comprising providing a blood sample from the animal or human being, and contacting the sample from the animal with the polypeptide of the invention, a significant release into the extracellular phase of at least one cytokine by mononuclear cells in the blood sample being indicative of the animal being sensitized. A positive response being a response more than release from a blood sample derived from a patient without the TB diagnosis plus two standard deviations. The invention also relates to the in vitro method for diagnosing ongoing or previous sensitization in an animal or a human being with a virulent mycobacterium, the method comprising providing a blood sample from the animal or human being, and by contacting the sample from the animal with the polypeptide of the invention demonstrating the presence of antibodies recognizing the polypeptide of the invention in the serum sample.

The immunogenic composition used for diagnosing may comprise 1-20, such as 2-20 or even 3-20 different polypeptides or fusion polypeptides, such as 3-10 different polypeptides or fusion polypeptides.

Diagnostic DNA

The nucleic acid probes encoding the polypeptide of the invention can be used in a variety of diagnostic assays for detecting the presence of pathogenic organisms in a given sample.

A method of determining the presence of mycobacterial nucleic acids in an animal, including a human being, or in a sample, comprising administering a nucleic acid fragment of the invention to the animal or incubating the sample with the nucleic acid fragment of the invention or a nucleic acid fragment complementary thereto, and detecting the presence of hybridized nucleic acids resulting from the incubation (by using the hybridization assays which are well-known in the art), is also included in the invention. Such a method of diagnosing TB might involve the use of a composition comprising at least a part of a nucleotide sequence as defined above and detecting the presence of nucleotide sequences in a sample from the animal or human being to be tested which hybridize with the nucleic acid fragment (or a complementary fragment) by the use of PCR technique.

Antibodies

A monoclonal or polyclonal antibody, which is specifically reacting with a polypeptide of the invention in an immunoassay, or a specific binding fragment of said antibody, is also a part of the invention. The antibodies can be produced by methods known to a person skilled in the art. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of a polypeptide according to the present invention and, if desired, an adjuvant. The monoclonal antibodies according to the present invention may, for example, be produced by the hybridoma method first described by Kohler and Milstein (Kohler and Milstein, 1975), or may be produced by recombinant DNA methods such as described in U.S. Pat. No. 4,816,567. The monoclonal antibodies may also be isolated from phage libraries generated using the techniques described by McCafferty et al (McCafferty, 1990), for example. Methods for producing antibodies are described in the literature, e.g. in U.S. Pat. No. 6,136,958.

A sample of a potentially infected organ or body fluid from an infected individual may be contacted with such an antibody recognizing a polypeptide of the invention. The demonstration of the reaction by means of methods well known in the art between the sample and the antibody will be indicative of an ongoing infection. It is of course also a possibility to demonstrate the presence of anti-mycobacterial antibodies in serum or other body fluids by contacting a serum sample from a subject with at least one of the polypeptide fragments of the invention and using well-known methods for visualizing the reaction between the antibody and antigen.

In diagnostics, an antibody, a nucleic acid fragment and/or a polypeptide of the invention can be used either alone, or as a constituent in a composition. Such compositions are known in the art, and comprise compositions in which the antibody, the nucleic acid fragment or the polypeptide of the invention is coupled, preferably covalently, to at least one other molecule, e.g. a label (e.g. radioactive or fluorescent) or a carrier molecule.

It will be understood that the following examples are illustrative of the present invention and are not a limitation thereof. A number of variations on the techniques, reagents, and conditions described in the following examples will be readily apparent to one of skill in the art.

Examples Example 1 Cloning and Expression of Low Oxygen Induced M. tuberculosis Antigens in E. coli.

A number of M tuberculosis genes are induced under low oxygen conditions. The upregulation of the genes listed in table 2 has been determined at either the mRNA (Sherman, 2001) or protein (Boon, 2001, Rosenkrands, 2002) level. The coding region of these selected antigens is amplified by PCR using the primer sets listed in Table 3.

TABLE 3 Primer sequences for PCR amplification of selected low oxygen induced antigens SEQ ID Rv no. NO: Primer sequence Rv0079 Fwd 92 CACCGTGGAACCGAAACGCAGTCG Rvs 93 TTATGCCAGACCGTCGGCA Rv0080 Fwd 94 CACCATGAGCCCGGGCTCG Rvs 95 TTACGGCGTACGCGAGTCAG Rv0081 Fwd 96 CACCGTGGAGTCCGAACCGCTGTA Rvs 97 TTACGTGGCCGAGCCGC Rv0363c Fwd 98 CACCATGCCTATCGCAACGCCC (fba) Rvs 99 TTAGTGGGTTAGGGACTTTCCGG Rv0569 Fwd 100 GGGGACAAGTTTGTACAAAAAAGCAGGCTTAAAGGCAAAGGTCGGGG AC Rvs 101 GGGGACCACTTTGTACAAGAAAGCTGGGTCCTACGTTCCCCTGGCAT GGA Rv0572c Fwd 102 CACCATGGGTGAGCACGCCATC Rvs 103 TTATAGGTCATCGGATTGAGGTGATC Rv0574c Fwd 104 CACCGTGGCTGGCAATCCTGATGT Rvs 105 TTACTCCTTGCTCGTTAGGTTGGC Rv1264 Fwd 106 CACCGTGACAGACCACGTGCGC Rvs 107 TTACGGTGACGAGCCGGC Rv1592c Fwd 108 CACCATGGTAGAGCCCGGCAATTTG Rvs 109 TTAGAGCGGACGGCGGCT Rv1733c Fwd 110 CACCATGATCGCCACAACCCGC Rvs 111 TTACCGCTGCGTGCAGAACA Rv1734c Fwd 112 CACCATGACCAACGTCGGTGACCA Rvs 113 TTATCCTGTTACTGCGGCGCA Rv1736c Fwd 114 CACCGTGACGGTGACACCACGGAC (narX) Rvs 115 TTACCACCCGCGCCGC Rv1737c Fwd 116 CACCATGAGAGGGCAAGCGGC (narK2) Rvs 117 TTACCTGGACGCCTCCTCACTC Rv1738 Fwd 118 CACCATGTGCGGCGACCAGTC Rvs 119 TTAATACAACAATCGCGCCGG Rv1739c Fwd 120 CACCATGATTCCCACGATGACATCG Rvs 121 TTAGCGCCGACGGAACG Rv1813c Fwd 122 GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATCACAAACCTCCGAC GC Rvs 123 GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAGTTGCACGCCCAGT TGAC Rv1997 Fwd 124 CACCTTGTCGGCGTCAGTGTCTGC (ctpF) Rvs 125 TTATGGCGGTTGCGCCC Rv1998c Fwd 126 CACCATGAGTTTCCACGATCTTCATCACC Rvs 127 TTACGTTGTACTCGTGCGGTTCTC Rv2003c Fwd 128 CACCGTGGTCAAGCGCTCTCGG Rvs 129 TTATTCCGACTCGAGTGGGTGA Rv2005c Fwd 130 CACCATGTCTAAACCCCGCAAGCA Rvs 131 TTACGACTGCCGTGCCACG Rv2007c Fwd 132 CACCGTGACCTATGTGATCGGTAGTGAGTG (fdxA) Rvs 133 TTAAGGGCACTCCACCGGGA Rv2028c Fwd 134 CACCATGAACCAATCACACAAACCCC Rvs 135 TTACAGATACTGCTGACCGACGACC Rv2029c Fwd 136 CACCATGACGGAGCCAGCGG (pfkB) Rvs 137 TTATGGCGAGGCTTCCGG Rv2030c Fwd 138 GGGGACAAGTTTGTACAAAAAAGCAGGCTTACTGATGACCGCAGCGG CT Rvs 139 GGGGACCACTTTGTACAAGAAAGCTGGGTCCTACAGACCGGTC GGGTAGGTTT Rv2031c Fwd 140 GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGCCACCACCCTTCCCGT (hspX) Rvs 141 GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAGTTGGTGGACCGGA TCTGAAT Rv2032 Fwd 142 CACCATGCCGGACACCATGGTG Rvs 143 TTAGTGATCCTTAGCCCGAACGTG Rv2428 Fwd 144 GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGCCACTGCTAACCA TTGGC (ahpC) Rvs 145 GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAGGCCGAAGCCTTGA GGAGT Rv2624c Fwd 146 CACCATGTCTGGGAGAGGAGAGCCG Rvs 147 TTAGCGAACGACAAGCACCGA Rv2625c Fwd 148 GGGGACAAGTTTGTACAAAAAAGCAGGCTTACGTGATGCGATCCCGCT Rvs 149 GGGGACCACTTTGTACAAGAAAGCTGGGTCCTACCCCGCATCGGAAA ACC Rv2627c Fwd 150 GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGGCAAGTTCTGCGA GCGA Rvs 151 GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAGGAACGGTCGCGCT GTGT Rv2628 Fwd 152 CACCATGTCCACGCAACGACCG Rvs 153 TTAACCGCAACGGCAATCTCA Rv2629 Fwd 154 CACCATGCGATCAGAACGTCTCCG Rvs 155 TTAGGATCTATGGCTGCCGAGTC Rv2630 Fwd 156 CACCATGCTGCACCGCGACGA Rvs 157 TTACACATCGAGCGTTACCGCAC Rv2659c Fwd 158 GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGTGACGCAAACCGGCAA Rvs 159 GGGGACCACTTTGTACAAGAAAGCTGGGTCCTACATCTCCTGGTTCT CGGCC Rv2780 Fwd 160 GGGGACAAGTTTGTACAAAAAAGCAGGCTTACGCGTCGGTATTCCGA CC Rvs 161 GGGGACCACTTTGTACAAGAAAGCTGGGTCCTACACGCTGGCGGGCTC Rv3126c Fwd 162 CACCATGGTCATCCGGTTTGATCAAATA Rvs 163 TTATGGATTGTCAATGACAGCCCA Rv3127 Fwd 164 CACCGTGCTCAAGAACGCAGTCTTGC Rvs 165 TTAAGGCGGGCTGAACCAACC Rv3128c Fwd 166 CACCGTGTGGTCCGCCTCGG Rvs 167 TTAGCCCGCCTTGATCAGGA Rv3129 Fwd 168 CACCGTGGTGCAAGGCCGCA Rvs 169 TTATCGCTGGTTGTGTGACGAG Rv3130c Fwd 170 CACCATGAATCACCTAACGACACTTGACG Rvs 171 TTACACAACCAGCGATAGCGCTC Rv3131 Fwd 172 CACCATGAACACCCATTTCCCGG Rvs 173 TTAGCACCGTTGTCGCAGTAGCT Rv3132c Fwd 174 CACCATGACAACAGGGGGCCTCG Rvs 175 TTACTGCGACAACGGTGCTGAC Rv3134c Fwd 176 CACCATGAGCGATCCTCGGCCA Rvs 177 TTACAAGTTGGCACTGCGTACCG Rv3841 Fwd 178 CCGGCTGAGATCTATGACAGAATACGAAGGGC (bfrB) Rvs 179 CCCCGCCAGGGAACTAGAGGCGGC Rv3842c Fwd 180 CACCATGACATGGGCCGACGAG (glpQ1) Rvs 181 TTAGCGAGTGGTCCCGTTCG Rv3908 Fwd 182 CACCGTGTCCGACGGCGAACAA Rvs 183 TTACGGCCCCGGCCC

PCR reactions were carried out using Platinum Tag DNA Polymerase (GIBCO BRL) in a 50 μl reaction volume containing 60 mM Tris-SO₄(pH 8.9), 18 mM Ammonium Sulfate, 0.2 mM of each of the four nucleotides, 0.2 μM of each primer and 10 ng of M. tuberculosis H37Rv chromosomal DNA. The reaction mixtures were initially heated to 95° C. for 5 min., followed by 35 cycles of: 95° C. for 45 sec, 60° C. for 45 sec and 72° C. for 2 min. The amplification products were precipitated by PEG/MgCl₂, and dissolved in 50 μL TE buffer.

DNA fragments were cloned and expressed in Gateway Cloning system (Life Technology). First, to create Entry Clones, 5 μL of DNA fragment was mixed with 1 μL of pDONR201, 2 μL of BP CLONASE enzyme mix and 2 μL of BP reaction buffer. The recombination reactions were carried out at 25° C. for 60 min. After Proteinase K treatment at 37° C. for 10 min., 5 μL of each sample was used to transform E. coli DH5α competent cells. Transformants were selected on LB plates containing 50 μg/mL kanamycin. One bacterial clone from each transformation was grown in 3 mL LB medium containing 50 μg/mL kanamycin and plasmid DNA was isolated (Qiagen).

Second, to create expression clones, 2 μL of each entry clone DNA was mixed with 1 μL of His-tagged expression vector (pDest17), 2 μL LR reaction buffer, 2 μL LR CLONASE enzyme mix and 3 μL TE. After recombination at 25° C. for 60 min. and Proteinase K treatment at 37° C. for 10 min., 5 μL of each sample was used to transform E. coli BL21-SI competent cells. Transformants were selected on LBON (LB without NaCl) plates containing 100 μg/mL ampicillin. The resulting E. coli clones express recombinant proteins carrying a 6-histine tag at the N-terminal. All clones were confirmed by DNA sequencing.

Recombinant proteins were purified from transformed E. coli BL21-SI cells cultured in 900 mL LBON medium containing 100 μg/mL at 30° C. until OD₆₀₀=0.4-0.6. At this point 100 mL 3 M NaCl was added and 3 hours later bacteria were harvested by centrifugation. Bacteria pellets were resuspended in 20 mL bacterial protein extraction reagent (Pierce) incubated for 10 min. at room temperature and pelleted by centrifugation. Bacteria were lysed and their DNA digested by treating with lysozyme (0.1 mg/mL) and DNase I (2.5 μg/mL) at room temperature for 30 minutes, with gentle agitation. The recombinant protein forms inclusion bodies and can be pelleted by centrifugation at 27.000×g for 15 min. Protein pellets were solubilized by adding 20 ml of sonication buffer (8 M urea, 50 mM Na₂HPO₄, 100 mM Tris-HCl, pH 8.0) and sonicating 5×30 sec pulses interrupted by a 30 sec pause. After another centrifugation at 27.000×g for 15 min., supernatants were applied to 10 mL TALON columns (Clontech). The columns were washed with 50 mL sonication buffer. Bound proteins were eluted by lowering pH (8 M urea, 50 mM Na₂HPO₄, 100 mM Tris-HCl, pH 4.5). 5 mL fractions were collected and analyzed by SDS-PAGE. Fractions containing recombinant protein were pooled. Further purification was achieved by anion- or cation-exchange chromatography on Hitrap columns (Pharmacia). Bound protein was eluted using a NaCl gradient from 0-500 mM in 3 M urea, 10 mM Tris-HCl, pH 8.0. All fractions were collected and analyzed on SDS-PAGE using Coomassie staining. Fractions containing recombinant protein were pooled. Final protein concentrations were determined by micro BCA (Pierce).

Example 2 Prophylactic Versus Therapeutic Vaccine

Murine Vaccination Models.

A prophylactic vaccine given prior to infection should induce an immune response sufficiently strong to prevent or dampen the initial proliferation of the bacteria in the acute phase and thereby reduce the ensuing disease. In the murine prophylactic vaccine model outlined in FIG. 1A, naïve mice are immunized 3 times, 2 weeks apart with recombinant antigens. Six weeks after the last immunization, the mice are given an aerosol infection with approximately 250 M. tuberculosis bacilli. The protective capacity of the vaccine is evaluated by enumeration of the bacteria in spleen and lung 6 weeks post-infection.

To define the optimal components for a therapeutic vaccine, a murine reactivation model of latent TB has been established (van Pinxteren, 2000) (FIG. 1B). An aerosol infection with approximately 250 M. tuberculosis bacilli is given and at the peak of infection 6 weeks later, the mice receive an 8-week course of anti-mycobacterial drug treatment of isoniazid and rifabutin given in the drinking water. This reduces the bacterial load in spleen and lung to a low level (about 500 bacteria per organ). This latent phase of low chronic infection is stable for 9-10 weeks after which a slow spontaneous reactivation occurs. The therapeutic vaccine is given as 3 subcutaneous (s.c.) immunizations about 5 weeks after cessation of drug treatment. The effect of the therapeutic vaccine is evaluated as protection against reactivation determined by enumeration of bacteria in spleen and lung 7 weeks after the last immunization.

The effect of the antigens in a prophylactic or a therapeutic vaccine.

BCG, ESAT6, and Rv2031c, one of the most prominent proteins induced under low oxygen conditions (Rosenkrands, 2002), were analyzed for their prophylactic and therapeutic vaccine potential. Naïve or latently infected C57Bl mice were immunized with one s.c. injection of 2.5×10⁵ BCG, or 3 s.c. immunizations of 10 μg of either recombinant ESAT6 or recombinant Rv2031c in a DDA/MPL adjuvant. The vaccinations were done in groups of 5 mice and protective capacity of the vaccines was evaluated as described above. FIG. 2 shows the bacterial load in the lung in the acute phase (A) and in the reactivation phase (B), after prophylactic and therapeutic vaccination respectively. ESAT6 (as previously described by Brandt, 2000) offers protection against acute phase infection at the level of BCG (FIG. 2A). However, neither of the two shows any protective effect against reactivation of the infection when given during latent infection (FIG. 2B). In contrast, Rv2031c, the low oxygen induced antigen, offers no protection against the acute phase of the infection when given as a prophylactic vaccine, but gives some protection against reactivation when given as a therapeutic vaccine. That is, some antigens, here exemplified by ESAT6, though potent as prophylactic vaccines have no effect as therapeutic vaccines. In contrast, other antigens, here exemplified by Rv2031c, can be efficient therapeutic vaccines although they have no effect or only negligible effect as prophylactic vaccines.

Example 3 Low Oxygen Induced Antigens, Rv2031c, as Therapeutic Vaccines

There is a high variability in bacterial load intrinsic to the reactivation model in the latent and reactivation phase. The analysis of Rv2031c as a therapeutic vaccine was therefore repeated in groups of eight mice. As in the previous experiments the mice were given 3 s.c. immunizations of 10 μg rRv2031c in DDA/MPL. The induced immune responses were analyzed one week post immunization. The mice were partially bled and the PBMC from the blood purified and analyzed for Rv2031c- and ESAT6 specific recall responses. Using ELIspot technique, the frequency of Rv2031c-specific and ESAT6-specific IFN-γ-producing cells were determined in both the rRv2031c immunized and the unimmunized group (FIG. 3). The rRv2031c immunization has increased the frequency of Rv2031c-specific IFN-γ producing cells by a factor of 43 as compared to the unimmunized group. In contrast, the frequency of ESAT6-specific IFN-γ producing cells is significantly higher in the unimmunized group. ESAT6 is an antigen produced in high amounts by the actively-growing M. tuberculosis bacteria. The level of the ESAT6 specific immune response in infected mice could therefore be indicative the degree of actively-growing infection in the animals. Recent reports have in fact demonstrated such a correlation between the level of ESAT6 response and degree of disease in both M. tuberculosis-infected humans and M. bovis-infected cattle (Doherty, 2002, Vordermeier, 2002). Therefore, the higher ESAT6 response in the unimmunized group of latently-infected mice could be indicative of a transition into the reactivation phase, where the bacteria are again beginning to multiply.

To analyze the epitope recognition pattern of Rv2031 c, fourteen overlapping peptides (each 20 amino acids long) covering the whole Rv2031c protein were synthesized. Initially the peptides were analyzed in 4 pools of 3-4 peptides. PBMCs from rRv2031c immunized latently-infected mice were incubated with the peptide pools (5 μg/ml per peptide) for 72 h. The specific peptide-induced IFN-γ production was quantitated in the supernatant in a standard sandwich ELISA using paired anti-murine IFN-γ antibodies (PharMingen) and recombinant IFN-γ (PharMingen) as standard. Both peptide pool 1-4 and 8-10 stimulated a significant IFN-γ response (FIG. 4A). The individual peptides of these two pools were re-analyzed (FIG. 4B). This clearly shows that the response to Rv2031c contains a dominant epitope, peptide 2 (PRSLFPEFSELFAAFPSFAG, aa 11-30 of SEQ ID NO:24), and a subdominant epitope, peptide 9 (RTEQKDFDGRSEFAYGSFVR, aa 81-100 of SEQ ID NO:24).

The therapeutic effect of the rRv2031c immunizations was analyzed 7 weeks after the last immunization. FIG. 5 shows the bacterial load in the lung (A) and the spleen (B) of both rRv2031c-immunized and unimmunized mice. There is a clear reduction in the level of bacteria in both organs in the rRv2031c-immunized group. That is, the induction of Rv2031c T cell responses can participate in keeping the latent infection in check.

Example 4 Low Oxygen Induced Antigens, Rv0569, as Therapeutic Vaccines

Rv0569 is also a low oxygen induced antigen described in WO0179274 and illustrates very well the potential as a therapeutic vaccine.

We have established a murine reactivation model of latent TB [van Pinxteren et al, 2000, 30:3689-98], which is a variant of the so-called Cornell model. An aerosol infection is allowed to be established and at the peak of infection 6 weeks after, the mice receive an 8-week course of anti-mycobacterial drug treatment of isoniazid and rifabutin given in the drinking water. This reduces the bacterial load in spleen and lung to a low level. This latent phase of low chronic infection is stable for 9-10 weeks after which a slow spontaneous reactivation can be detected. This model is used to analyze the protective effect of a post exposure vaccine on reactivation.

Rv0569, which is highly up regulated under low oxygen growth conditions [Rosenkrands et al, 2002, 184(13): 3485-91], was analyzed for its ability to protect against reactivation given as a therapeutic vaccine in the latent phase of TB infection. Latent infected C57B1 mice were vaccinated with 3 s.c. injections of 3 μg recombinant Rv0569 and for comparison with 3 s.c. injections of 3 μg recombinant ESAT6 or one s.c. injection of BCG. The effect of the vaccine is evaluated 7 weeks after the last immunization. The induced immune responses were analyzed for Rv0569 or ESAT6 specific responses in an in vitro recall assay. Isolated splenocytes were incubated with 1 μg/ml of Rv0569 or 1 μg/ml of ESAT6 for 72 h. The produced IFNγ in the culture supernatant was quantitated in a standard sandwich ELISA. FIG. 6 shows a nice Rv0569 specific IFNγ response induced in the Rv0569 vaccinated group with practically no response in the un-vaccinated group. The ESAT6 vaccination enhanced the ESAT6 specific response though a significant ESAT6 response persisted in the un-vaccinated latent infected group.

The Rv0569 induced protection against reactivation was determined by enumeration of bacteria in spleen and lung 7 weeks after the last immunization. FIG. 7 shows the bacterial load in the lung and the spleen of both Rv0569-vaccinated, ESAT6-vaccinated, BCG vaccinated and un-vaccinated latently infected mice. There is a clear reduction in the level of viable bacteria in both spleen and lungs of the Rv0569 vaccinated mice, whereas neither ESAT6 nor BCG are able to inhibit the growth of the M. tuberculosis bacteria when given as a vaccine during latent infection. That is, the induction of Rv0569 T cell responses can participate in keeping the latent infection in check.

REFERENCES

Anon. 2001. Global Tuberculosis Control. WHO Report.

Boon, C., et al. 2001. J. Bacteriol, 183, 2677-2676.

Brandt, L., et al. 2000 Infect. Immun. 68:2; 791-795.

Cote-Sierra J, et al 1998, Gene October 9; 221(1):25-34

Doherty T M et al., 2002, J Clin Microbiol. February; 40(2):704-6.

Florczyk, M. A., et al. 2001. Infect Immun, 69, 5777-5785.

Gosselin et al., 1992. J. Immunol. 149: 3477-3481

Harboe, M., et al 1998 Infect. Immun. 66:2; 717-723

Honer zu Bentrup, K. et al., 2001. Trens Immunol. 9 597-605

Kilgus J et al, J Immunol. 1991 Jan. 1; 146(1):307-15

Kohler and Milstein, Nature, 256:495 (1975)

Lowrie, D. B. et al 1999, Nature 400: 269-71

Lustig et al 1976, Cell Immunol 24(1):164-7

Manganelli, et al. 2001. Mol Microbiol, 41, 423-437.

McCafferty, et al. 1990. Nature, 348, 552-554.

Merrifield, R. B. Fed. Proc. Am. Soc. Ex. Biol. 21: 412, 1962 and J. Am. Chem. Soc. 85: 2149, 1963

Monahan, I. M. et al. 2001. Microbiology, 147, 459-471.

Mowat et al 1991, Immunology 72(3):317-22

Nagai et al 1991, Infect. Immun 59:1; 372-382

Olsen A. W et al, Eur J Immunol. 2000 June; 30(6):1724-32

Danish Patent application PA 2000 00666 “Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis”

Danish Patent application PA 1999 01020 (WO 01/23388) “Tuberculosis vaccine and diagnostic based on the Mycobacterium tuberculosis esat-6 gene family”.

U.S. patent application Ser. No. 09/0505,739 “Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis”

Pearson, W. R. et al. 1988. Proc Natl Acad Sci USA, 85, 2444-2448.

Ravn, P. et al 1999. J. Infect. Dis. 179:637-645

Rolph, M. S, and I. A. Ramshaw. 1997. Curr. Opin. Immunol. 9:517-24

Rosenkrands, I., et al 1998, Infect. Immun 66:6; 2728-2735

Rosenkrands, I., et al. 2002. Journal of Bacteriology, 184: 3485-3491.

Sambrook et al Molecular Cloning; A laboratory manual, Cold Spring Harbor Laboratories, NY, 1989

Sherman, D. R., et al. 2001. PNAS, 98, 7534-7539.

Sinigaglia F et al. Nature 1988 Dec. 22-29; 336(6201):778-80

Skjøt, R.L.V., et al 2000, Infect. Immun 68:1; 214-220

Stryhn, A., et al 1996 Eur. J. Immunol. 26:1911-1918

Thompson J., et al Nucleic Acids Res 1994 22: 4673-4680

Ulmer J. B et al 1993, Curr. Opin. Invest. Drugs 2(9): 983-989

van Pinxteren L. et al. Eur J Immunol 2000, 30: 3689-3698.

Vordermeier, H. M. et al. 2002. Infect. Immun., 70, 3026-3032.

All documents listed above,and the sequence listing, are incorporated by reference herein. A variety of modifications and variations on the processes, conditions, reagents and compositions described herein will be readily apparent to one of skill in the art given the teachings of the present invention. Such modifications and variations are within the scope of the invention as set forth in the following claims. 

1. A therapeutic vaccine against tuberculosis comprising a mycobacteria polypeptide having amino acid sequence SEQ ID NO: 33 and a pharmaceutically acceptable polymeric carrier bound to the polypeptide or a pharmaceutically acceptable adjuvant.
 2. The therapeutic vaccine according to claim 1, wherein said polypeptide is fused to at least one fusion partner which is an antigen expressed by bacteria within the mycobacteria family heterologous to said polypeptide.
 3. The therapeutic vaccine according to claim 1, wherein said polypeptide is lipidated thereby providing a self-adjuvanting effect of the polypeptide.
 4. The therapeutic vaccine according to claim 1, which comprises a polymeric carrier bound by covalent or non-covalent interactions to said polypeptide.
 5. The therapeutic vaccine according to claim 5, wherein the polymeric carrier is a polystyrene.
 6. The therapeutic vaccine according to claim 2, wherein the fusion partner is selected from the polypeptides of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, and
 45. 7. The therapeutic vaccine according to claim 6, wherein the polypeptides are recombinant or synthetic and are delivered in a delivery system comprising an adjuvant.
 8. The therapeutic vaccine according to claim 2, wherein said at least one fusion partner is an antigen expressed by bacteria within the mycobacteria family other than a polypeptide selected from SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, and
 45. 9. The therapeutic vaccine according to claim 8, wherein said at least one fusion partner is selected from the group consisting of ESAT-6, ESAT-6-Ag85B, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64, MPT64, Ag85A, Ag85B (MPT59), MPB59, Ag85C, 19 kDa lipoprotein, and MPT32.
 10. The therapeutic vaccine according to claim 8, wherein the polypeptides are recombinant or synthetic and are delivered in a delivery system comprising an adjuvant.
 11. A therapeutic vaccine against tuberculosis comprising one or more mycobacteria polypeptides which are upregulated or expressed during the latent stage of the mycobacteria infection which is characterized by low-oxygen tension in the microenvironment of the mycobacteria and (i) a pharmaceutically acceptable polymeric carrier bound to the one or more polypeptides or (ii) a pharmaceutically acceptable adjuvant, wherein said one or more polypeptides has the amino acid sequence of SEQ ID NO: 33, wherein said one or more polypeptides is fused to at least one mycobacteria fusion partner.
 12. The therapeutic vaccine according to claim 11, where the polypeptides are recombinant or synthetic and are delivered in a delivery system comprising an adjuvant.
 13. The therapeutic vaccine according to claim 11, wherein the fusion partner is selected from SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, and
 45. 14. The therapeutic vaccine according to claim 13, wherein the fusion partner is an antigen expressed by bacteria within the mycobacteria family other than a polypeptide selected from SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, and
 45. 15. The therapeutic vaccine according to claim 14, wherein the fusion partner is selected from the group consisting of ESAT-6, ESAT-6-Ag85B, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64, MPT64, Ag85A, Ag85B (MPT59), MPB59, Ag85C, 19 kDa lipoprotein, and MPT32.
 16. A method for inducing an immune response to latent tuberculosis in an individual, said method comprising the step of delivering a composition comprising one or more mycobacteria polypeptides which are upregulated or expressed during the latent stage of the mycobacteria infection, wherein one polypeptide has the amino acid sequence of SEQ ID NO:
 33. 17. The method according to claim 16, wherein the polypeptides are recombinant or synthetic and are delivered in a delivery system comprising an adjuvant.
 18. The method according to claim 16, wherein the fusion partner is , selected from SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, and
 45. 19. The method according to claim 16, wherein the fusion partner is an antigen expressed by bacteria within the mycobacteria family other than a polypeptide selected from SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, and
 45. 20. The method according to claim 19, wherein the fusion partner is selected from the group consisting of ESAT-6, ESAT-6-Ag85B, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64, MPT64, Ag85A, Ag85B (MPT59), MPB59, Ag85C, 19 kDa lipoprotein, and MPT32. 